FR2895239A1 - Cosmetic use of a neuropeptide Y antagonistic compound to prevent and/or treat e.g. disorders of damaged or fragile lips, dry lips, rednesses, desquamations, chapped lips, irritable/sensitive lips, dysesthesic feelings and painful feelings - Google Patents

Abstract

Cosmetic use of a neuropeptide Y (NPY) antagonistic compound to prevent and/or treat the disorders of damaged or fragile lips. Independent claims are included for: (1) a composition comprising the NPY antagonistic compound in a medium, in the form of lipstick, liquid gloss, lip paste, lip liner pencil, lip balm or lip varnish; and (2) cosmetic process of embellishing the damaged lips and/or treating the fragile/sensitive lips, comprising applying the composition on the lips. ACTIVITY : Dermatological. MECHANISM OF ACTION : Neuropeptide Y antagonist.

Description

The field of the invention relates to the care of the lips, in particular the

  care of damaged or sensitive lips.

  By lip, it will be understood according to the present invention the red lip, and more particularly the vermilion. The red lip is the free edge of the lip which includes an internal mucous portion, or wet lip, in continuity with the oral mucosa and an external, visible, semi-mucous or dry lip called vermilion. The posterior border of the vermilion is defined by the point of contact when the mouth is closed, its contour consists of the cutaneous-mucous junction line. Vermilion is red in fair-skinned and pigmented subjects in colored subjects.

  The red lips are a semi-mucous membrane, that is to say a mucous membrane covered with a very fine epithelium of a few layers of cells, so they do not benefit from the protection of the epidermis and the stratum corneum like the other parts of the face. However, like other parts of the face, the lips are constantly exposed to external aggressions (cold, hot, wind, dry air), they are also a constantly moving area and therefore subject to mechanical stress (speech, expression, food .. .) and wet (saliva, drink ...).

  Thus, it is a fragile area and subject to permanent attacks, so they are frequently weakened, sensitized or even damaged.

  To protect the lips against drying out, it is generally used stick lip balms, containing treating oils, generally of plant origin such as triglycerides (see for this purpose the document JP-A-04 360 810). Unfortunately, even in high quantities, these oils do not allow sufficient treatment of the lips, especially when the latter are swollen or damaged by cracks or cracks.

  In addition, some people have more sensitive skin than others, these people have a particular reactivity of the skin but also of the lips. Subsequently, we will assimilate sensitive skin and lip.

  The cutaneous reactivity is translated classically by the manifestation of signs of discomfort in response to the contacting of the subject with a triggering element that can have various origins. It may be the application of a cosmetic product on the surface of the skin or sensitive lips, the taking of food, exposure to sudden changes in temperature, air pollution and / or ultraviolet or infrared rays. There are also associated factors like age and skin type. Sensitive skin is therefore more common among dry or oily skin than normal skin. The appearance of these signs of discomfort, which appear in the minutes following the contact of the subject with the triggering element, is one of the essential characteristics of sensitive skin. It is mainly dysaesthetic sensations. By dysaesthesic sensations are meant more or less painful sensations felt in a cutaneous area such as tingling, tingling, itching, burning, heating, discomfort, tightness, etc. These subjective signs most often exist in the absence of visible clinical signs such as redness and flaking. It is now known that these skin irritation and intolerance reactions are notably related to a release of neuropeptides by the nerve endings of the epidermis and the dermis.

  As opposed to skins described as allergic, the reactivity of sensitive skin is not an immunological process. Its response mechanism is called "nonspecific". It is, in this respect, to distinguish skin showing inflammatory and allergic reactions such as dermatitis, eczema, and / or ichthyosis, and against which a number of treatments have already been proposed.

  For obvious reasons, the absence of visible signs makes it difficult to diagnose sensitive skin. Most often this diagnosis is based on the interrogation of the patient. This symptomatology also has the advantage of making it possible to differentiate sensitive skin, irritation or contact allergy for which, on the other hand, there are visible inflammatory signs.

  Consequently, the development of "sensitive skin" products required the availability of tools for assessing the sensory response of the skin. The first tools were inspired from their conception of the essential characteristic of sensitive skin to know the presence of signs of discomfort induced by a topical application. Thus, the "stinging test" with lactic acid was the first test proposed. It is performed by recording tingling sensation reported by a volunteer after application of a lactic acid solution at 10% on the wings of the nose. Subjects reporting moderate or severe tingling sensations are referred to as "stingers" and are considered to be sensitive skin. Because of this cutaneous sensitivity to the topical application of product, these subjects are then selected to test products known as sensitive skin. More recently, to specifically activate the peripheral nerve endings, involved in the discomfort and called nociceptors, recently identified as being involved in sensitive skin, new tests have been proposed that use precisely other discomfort inducers such as capsaicin. This second type of test, described in application EP 1 374 913, is also another particularly useful means for the diagnosis of sensitive skin.

  For the purposes of the present invention, sensitive skin or lips cover irritable skin or lips and intolerant skin or lips. An intolerant skin is a skin that reacts with sensations of heating, tugging, tingling and / or redness, to various factors such as the application of cosmetic or dermatological products or soap. In general, these signs are associated with erythema and hyper-seborrhoeic or acneic skin, or even rosacea, with or without darter. Irritable skin is a skin that reacts with pruritus, that is to say itching or tingling, to various factors such as the environment, emotions, food, wind, friction, razor , hard water with a high concentration of limestone, variations in temperature, humidity or wool.

  Thus, it is useful to identify new assets for the care of weakened, damaged and / or sensitive lips.

  The Applicant has recently discovered the existence of an important expression of NPY in the lips. This observation distinguishes the lip from the other innervated facial areas of the face, such as the eyelids where the expression of NPY is weak.

  The invention relates to the use of at least one antagonist of neuropeptide Y for the preparation of a composition for the care of the lips, in particular for the care of damaged and / or sensitive lips. By damaged lips, one understands as well lips weakened (for example by the cold) which can be desiccated and / or to present rednesses, desquamations, cracks and / or swellings, that lips painful and / or irritated and / / or cracked and / or showing one or more signs of inflammation (erythema, pain, heat and edema).

  As for sensitive lips, it may be irritable or intolerant lips, they are characterized by dysaesthesic sensations: more or less painful sensations, tugging, tingling, tingling, heating, itching, discomfort.

  Neuropeptide Y (NPY) is a peptide of 36 amino acids highly expressed in the central nervous system. It is a mediator who plays an important role in energy homeostasis. NPY is an extremely potent stimulator of eating behavior, it has been shown that NPY is associated with a greater body fat mass and more food intake is the orexigenic effect (PNAS 1985, 82, 3940 -3943).

  The pharmacological effects of NPY on pain have also been known for a long time (J. Pharma, Exp Ther 1991, 258, 243-248). From an anatomical point of view, pain stimuli are carried by sensory nerve fibers from the dorsal root ganglia of the spinal cord. Within these ganglia, nociceptive neurons are characterized by their small size. Their central axonal endings are found in the superficial layers of the dorsal horn of the spinal cord, from where the signal is transmitted to supraspinal structures. The expression of Y1 receptors at NPY by these small sensory neurons (PNAS 1997, 94, 729-734) would explain the analgesic effects observed in animals when administering specific agonists (Brain 1999, 833, 251-257 ). At the same time, the neuropeptide Y is involved peripherally, and in particular in the skin and the mucous membranes, in neurogenic inflammation where it promotes the release of substance P via the activation of Y1 subtype NPY receptors. Several other physiological roles have been assigned to NPY: circadian rhythm control, sexual function, anxiety, vascular resistance, and control of immune processes. To date, several NPY receptors have been characterized: Y1, Y2, Y5 and Y6 (m / s 2001, 17, 519-522). The role or roles of each of these receptors are not yet fully understood. In addition to the roles described below, Y1, as well as Y5, would intervene in the orexigenic effect (food control). The Y2 receptor has been detected in sensory neurons only after injury to the sciatic nerve and the induction of its expression is believed to be the basis of the analgesic effects of Y2 agonists.

  Finally, the effects of NPY can be variable from one organ to another, in particular, NPY is a powerful vasoconstrictor in the heart and brain but acts as a vasodilator in the skin (Wallengren et al. J. Investig.Dermatol, Symp., Proc., 1997, 2 (1) 49-55).

  Thus, the invention relates to the cosmetic use of at least one neuropeptide Y (NPY) antagonist compound for the care of weakened lips, in particular, for preventing and / or treating disorders associated with weakened lips and / or damaged, such as dry lips and / or redness and / or peeling and / or chapped lips. The NPY antagonist compound thus permitting, in particular, to reduce the redness of the lips to restore a uniform color.

  The invention also relates to the cosmetic use of at least one neuroptide Y (NPY) antagonist compound for preventing and / or treating sensitive lips, in particular, for preventing and / or treating irritable or intolerant lips. It is more specifically to treat dysaesthesic sensations and / or more or less painful sensations and / or tugging and / or tingling and / or tingling and / or heating and / or itching and / or discomfort.

  The present invention also relates to the use of at least one neuropeptide Y (NPY) antagonist compound for the preparation of a composition for the treatment of painful lips and / or having one or more signs of inflammation and / or or irritated and / or cracked.

  By virtue of its activities, the NPY antagonist compound may be incorporated into any composition intended to be applied topically to the lips.

  Thus, according to another of its objects, the invention relates to compositions comprising, in a physiologically acceptable medium, at least one NPY antagonist compound, characterized in that it is in the form of a lipstick, d a liquid gloss, a lipstick, a lip contour pencil, a lip balm, or a lip polish. The compositions may have as their destination the protection, repair, care or treatment of the lips. It may also be makeup composition that may, for example, both to treat and hide skin disorders of the lips.

  Another object of the invention relates to a cosmetic process for beautifying lips, treating weakened lips or sensitive lips, comprising applying to the lips a composition comprising at least one NPY antagonist.

  The NPY antagonist compounds are either chemical, peptide or non-peptide molecules, or any type of extract characterized by an NPY antagonist type activity, preferentially Y1 type.

  These compounds can be identified on the basis of a receptor binding to the NPY Y1 receptor, for example by the methods described by Fuhlendorf J. et al (PNAS-USA, 1990, 87, p182) or by Wieland et al. (J. Pharmacol Exp Ther, 1995, 275, 143-149). The antagonistic nature of the NPY of the compounds can also be demonstrated by studies on isolated organs and more particularly in the rat "vas deferens" model, in particular according to the protocol described in Regulatory Peptides 1986, 13, 307-318.

  As an example of NPY antagonists, mention may be made of all the NPY antagonist compounds listed in EP 0 838 217.

  1. Compounds of formula (I) Embedded image in which - Art represents naphthyl, phenyl, quinolyl or isoquinolyl optionally substituted by Cl, F, (C 1 -C 4) alkyl, (C 1 -C 4); C1-C4) alkoxy, hydroxyl or (C1-C4) dialkylamino; Ar 2 represents phenyl or thienyl, optionally substituted by Cl, F, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy or hydroxyl; - R1, R2 and R'2 represent independently of each other hydrogen, (C1-C4) alkyl or R1 represents nothing and N is bonded to Ar2 and optionally R2 and R'2 form a double bond, or R1 or R2 is bonded to Ar2 and represents (C1-C3) alkylene; -R3 and R4, which are identical or different, represent hydrogen, (C1-C4) alkyl or form, with the nitrogen atom to which they are bonded, a (C5-C7) saturated heterocycle chosen from pyrrolidine, piperidine and hexahydroazepine; - Z1 represents (C1-C12) alkylene interrupted or optionally substituted with (C5-C7) cycloalkyl or phenyl; Q 1 represents methyl, amino, (C 1 -C 4) alkoxycarbonylamino, (C 1 -C 4) alkylamino, di (C 1 -C 4) alkylamino, pyrrolidinyl, piperidino, morpholino, piperazinyl, (C 1 -C 4) alkyl-4-piperazinyl, amidino, (C1-C4) alkylamidino, guanidino, (C1-C4) alkylguanidino, pyridyl, imidazolyl, pyrimidinyl, indolyl, hydroxy, (C1-C4) alkoxy, (C2-C8) alkoxycarbonyl, N- [amino-C1-C4] alkyl ] -N - [(C1-C4) alkyl] amino, carbamoyl or phenyl optionally substituted with Cl, F, (C1-C4) alkyl, (C1-C4) alkoxy or hydroxyl; Q2 represents hydrogen or (C1-C4) alkyl; - Q3 represents hydrogen or (C1-C4) alkyl or Q1 and Q3 are linked to form a heterocycle and together represent (C2-C3) alkylene while Z1 represents nothing, in the form of pure enantiomers or their mixtures in any proportions, as well as their addition salts with acids, prepared according to EP 0 614 911.

  II - The analogues of raloxifene, in particular a) The compounds of formula (II) H) in which: - A is -O-, -S (O) m-, -N (R 6) -, - (CH 2) 2 - or -CH = CH-; R 6 is hydrogen or (C 1 -C 6) alkyl, and m is 0, 1, or 2; X is a bond or a (C1-C4) alkylene; R 2 is a group of formula in which R 4 and R 5 are independently a (C 1 -C 6) alkyl or, together with the nitrogen atom to which they are bonded, form a heterocyclic group chosen from hexamethyleneiminyl, piperazino and heptamethyleneiminyl, 4 methylpiperidinyl, imidazolinyl, piperidinyl, pyrrolidinyl or morpholinyl; R is a hydroxy, a halogen, a hydrogen, a (C 3 -C 8) cycloalkyl, a (C 2 -C 7) alkanoyloxy, a (C 1 -C 6) alkoxy, or a phenyl, said phenyl being optionally substituted with one, two or three substituents selected from the group consisting of (C1-C4) alkyl, (C1-C4) alkoxy, nitro, chlorine, fluorine, trifluoromethyl, -OSO2- (C1-C10) alkyl or -OC (O) -NH-R ; - R, is hydroxy, halogen, hydrogen, (C3-C8) cycloalkyl, (C2-C7) alkanoyloxy, (C1-C6) alkoxy, or phenyl, said phenyl may be optionally substituted with one, two or three substituents selected from group consisting of (C1-C4) alkyl, (C1-C4) alkoxy, nitro, chlorine, fluorine, trifluoromethyl, -OSO2- (C1-C10) alkyl or -OC (O) -NH-R3; wherein each R 3 is independently (C 1 -C 6) alkyl, (C 3 -C 8) cycloalkyl, unsubstituted or substituted phenyl wherein the substituent is halogen, (C 1 -C 6) alkyl or (C 1 -C 6) alkoxy; with the limitation that when X is a bond and A is -S-, then R and R 1 are not both selected from the group consisting of hydroxy, methoxy and (C 2 -C 7) alkanoyloxy; as well as its salts or solvates, preparable according to WO 96/12489, in particular a compound chosen from: 3- (4-methoxyphenyl) -4- [4- (2-pyrrolidin-1-ylethoxy) benzoyl] -1,2-dihydronaphthalene 3-phenyl-4- [4- (2-pyrrolidin-1-ylethoxy) benzoyl] -7-methoxy-1,2-dihydronaphthalene, 3- (4-methoxyphenyl) -4- [4- [2- (piperidine) 1-yl) ethoxy] benzoyl] -1-, 2-dihydronaphthalene, 3- (4-hydroxyphenyl) -4- [4- [2- (pyrrolidin-1-yl) ethoxy] benzoyl] -1,2-dihydronaphthalene 3- (4-methoxyphenyl) -4- [4- [2- (hexamethyleniminimin-1-yl) ethoxy] benzoyl] -1,2-dihydronaphthalene, 6) 3- (4-methoxyphenyl) -4- [4- 2- (Piperidin-1-yl) ethoxy] benzoyl] -1,2-dihydronaphthalene, 3- (4-methoxyphenyl) -4- [4- [2- (piperidin-1-yl) ethoxy] benzoyl] -7- methoxy-1,2-dihydronaphthalene, 3- (4-methoxyphenyl) -4- [4- [2- (N-methyl-1-pyrrolidinium) ethoxy] benzoyl] -1,2-dihydronaphthalene, 3- (4-methoxyphenyl) ) 4- [4- (2-Dimethylaminoethoxy) benzyl] -1,2-dihydronaphthalene, 8 3- (4-methoxyphenyl) -4- (4-diethylaminoethoxybenzoyl) -1,2-dihydroxybenzoyl; ydronaphthalene, 3- (4-methoxyphenyl) -4- (4-diisopropylaminoethoxybenzoyl) -1,2-dihydronaphthalene, 2- (4-hydroxyphenyl) -3- [4- [2- (hexamethyleneimin-1-yl) ethoxy] benzoyl ] Hydroxybenzofuran, 2- (4-hydroxyphenyl) -3- [4- [2- (piperidin-1-yl) ethoxy] benzoyl] -6-hydroxybenzofuran, 2- (4-hydroxyphenyl) -3- [4] - [2-pyrrolidin-1-yl) ethoxy] benzoyl] -6-hydroxybenzofuran, 2- (4-hydroxyphenyl) -3- [4- [2- (N, N-diethylamino) ethoxy] benzoyl] -6-hydroxybenzofuran 2- (4-hydroxyphenyl) -3- [4- [2- (N, N-diisopropylamino) ethoxy] benzoyl] -6-hydroxybenzofuran, 2- (4-hydroxyphenyl) -3- [4- [2 (N N, N-dimethylamino) ethoxy] benzoyl] -6-hydroxybenzofuran, 1-ethyl-2- (4-methoxyphenyl) -3- [4- [2- (piperidin-1-yl) ethoxy] benzoyl] -6-hydroxyindole, 2- (4-Methoxyphenyl) -3- [4- [2- (hexamethyleniminimin-1-yl) ethoxy] benzoyl] -6-methoxybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- (piperidine) 1-yl) ethoxy] benzoyl] -6-methoxybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- (pyrrolidin-1-yl) ethoxy] benzoyl] -6-methoxybenzofuran 2- (4-methoxyphenyl) -3- [4- [2- (N, N -diethylamino) ethoxy] benzoyl] -6-methoxybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- N, N-Diisopropylamino) ethoxy] benzoyl] -6-methoxybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- (N, N-dimethylamino) ethoxy] benzoyl] -6-methoxybenzofuran, 1-ethyl 2- (4-methoxyphenyl) -3- [4- [2 (piperidin-1-yl) ethoxy] benzoyl] -6-methoxyindole, 2- (4-methoxyphenyl) -3- [4- [3- (hexamethylene) -1- 1-yl) propoxy] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (hexamethyleneimin-1-yl) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-Methoxyphenyl) -3- [4- [3- (piperidin-1-yl) propoxy] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (pyrrolidine)]; 1-yl) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (N, N-diethylamino) ethoxy] benzoyl] benzo [b] thiophene, 2- ( 4-methoxyphenyl) -3- [4- [2- (N, N-diisopropylamino) ethoxyl] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (N, N) -N -dimethylamino) ethoxy] benzoyl] -benzo [b] thiophene, 2- (4-chlorophenyl) enyl) -3- [4- [2- (hexamethyleneimin-1-yl) ethoxy] benzoyl] -6-hydroxybenzo [b] thiophene, 2- (4-hydroxyphenyl) -3- [4- [2- (piperidine) 1-yl) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-hydroxyphenyl) -3- [4- [2- (pyrrolidin-1-yl) ethoxy] benzoyl] benzo [b] thiophene, 2- ( 4-hydroxyphenyl) -3- [4- [2- (N, N -diethylamino) ethoxyl] benzoyl] benzo [b] thiophene, 2- (4-hydroxyphenyl) -3- [4- [2- (N, N) -N diisopropylamino) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-hydroxyphenyl) -3- [4- [2- (N, N-dimethylamino) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-diisopropylamino) ethoxy] benzoyl] benzo [b] thiophene chlorophenyl) -3- [4- [2- (pyrrolidin-1-yl) ethoxy] benzoyl] benzo [b] thiophene-1 -oxide, 2- (4-chlorophenyl) -3- [4- [2 (piperidin) 1-yl) ethoxy] benzoyl] benzo [b] thiophene-1 -oxide, [6- (n-butylsulfonyl) -2- [4- (n-butylsulfonyl) phenyl] benzo [b] thien-3-yl] [4- [2- (1-Piperidinyl) ethoxy] phenylmethanone, [6- (n-pentylsulfonyl) -2- [4- (n-pentylsulfonyl) phenyl] benzo [b] thien-3-yl] [4 [2- (1-piperidinyl) ethoxy] phenylmethanone (1-Piperidinyl) ethoxy] phenyl] methanone, [6- (n-hexylsulfonyl) -2- [4- (n-hexylsulfonyl) phenyl] benzo [b] thi n-3-yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (n-butylsulfonyl) -2- (4- (n-butylsulfonyl) phenyl] benzo [b] thien-3 -yl] [4- [3- (1-piperidinyl) propyloxy] phenyl] methanone, [6- (n-butylsulfonyl) -2- [4- (n-butylsulfonyl] phenyl] benzo [b] thien-3-yl] - [4- [2- (1-pyrrolidinyl) ethoxy] phenyl] methanone, [6-hydroxy-2- [4- (n-butylsulfonyl) phenyl] benzo [b] thien-3-yl] - [4- [ 2 (1-Piperidinyl) ethoxy] phenyl] methanone, [6-n-butylsulfonyl-2- [4-hydroxyphenyl] benzo [b] thien-3-yl] - [4- [2 (1-piperidinyl) ethoxy] phenyl] ] methanone, [6- [N- (4-chlorophenyl) carbamoyl] -2- [4- [N- (4-chlorophenyl) carbamoyl] phenyl] benzo [b] thien-3-yl] [4- [2- (1-Piperidinyl) ethoxy] phenyl] meth anone, [6- (N- (n-butyl) carbamoyl] -2- [4- [N- (n-butyl) carbamoyl] phenyl] benzo [b] thien-3 -yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N-methylcarbamoyl) -2- [4- (N-methylcarbamoyl) phenyl] benzo [b] thien-3-yl ] [- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N-ethylcarbamoyl) -2- [4- (N-ethylcarbamoyl) phenyl] benzo [b] thien n-3-yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N-isopropylcarbamoyl) -2- [4- [N-isopropylcarbamoyl] phenyl] benzo [b] thien-3 -yl] [4 - [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N-cyclohexylcarbamoyl) -2- [4- (N-cyclohexylcarbamoyl) phenyl] benzo [b] thienyl-3-yl ] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone and their salts and solvates.

  (b) The compounds of formula (III) CH2CH2R2 in which Ro and R30, independently, represent H, CH3, -CO- (C1-C6) alkyl, optionally substituted phenyl and R20 represents pyrrolidino, piperidino, hexamethylenimino or their salts or solvates pharmaceutically acceptable, NPY-antagonists described in US Pat. No. 5,504,094, in particular the compound of formula (III), in which Ro and R30 are both hydrogen and R20 is pyrrolidino, as well as their salts and solvates. III - Phenylsulfonylquinolines of formula (IV): ## STR1 ## in which Ry is an optionally substituted aryl, - R'y is -NO2, -ON, -CO2R3y in which R3y is H, alkyl or aryl, -SO2R3y in wherein R3y is as defined above, or where R3y is as defined above, or wherein R3y is as defined above, - R2y is -NH2, -OH or -SH and its salts, described in US 5,552,411, including 8-amino-6- (2-isopropylphenylsulfonyl) 5-nitroquinoline known as PD-160170 and 8-amino-6- (4-aminophenylsulfonyl) -5-nitroquinoline, known as the PD-9262 code described in Bioorganic and Medicinal Chemistry Letters, 1996, 6, 15, 1809-1814. IV - Bénextramine and its analogs described in J. Med. Chem. 1993, 36, 272-279, in Eur. J. Pharmacology 1994, 37, 2242-2248 and in Current Pharmaceutical Design, 1995, 1, 295-304, especially SC3117, SC3199, CC217 and CC2137.

  V - Inositol phosphate derivatives, in particular:

  (a) The specific isomers of inositol triphosphate, including D-myo-inositol-1,2,6-triphosphate, myo-inositol-1,2,3-triphosphate and L-myo-inositol-1,3, 4-triphosphate, described as NPY antagonists in WO 92/00079 and US 5,128,332. B) Inositol monophosphate in acid form and its salts, in particular sodium, potassium, calcium or zinc salts, described as NPY-antagonists in WO 92/00744

  VI - Compounds of formula (V) in which: - Ar 'is phenyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each optionally being mono or disubstituted by a halogen, a hydroxy, or a linear or branched lower alkyl chain having 1 to 6 carbon atoms; A ', W', X ', Y', and R are the same or different and represent hydrogen, halogen, hydroxy, linear or branched lower alkoxy chain having 1 to 6 carbon atoms; 1 and R'2 are the same or different and represent hydrogen, a linear or branched lower alkyl chain having 1 to 6 carbon atoms; R'3 and R'4 are identical or different and represent a hydrogen, a straight or branched lower alkyl chain having 1 to 6 carbon atoms; and R'9 represents hydrogen, a straight or branched lower alkyl chain having 1 to 6 carbon atoms, or phenyl; and their salts, preparable as described in WO 96/14307, 1-cyano-1- (4-phenylpiperazin-1-yl) cyclohexane, 1-phenyl-1- (4-phenylpiperazin-1-yl) cyclohexane, 1- ( 3-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-methoxyphenyl) -1- [4- (2-pyrimidinyl) piperazin-1-yl] cyclohexane, 1- (3-methoxyphenyl) ) -1- [4- (2-pyridinyl) piperazin-1-yl] cyclohexane, 1- (3-methoxyphenyl) -1- [4- (2-fluorophenyl) piperazin-1-yl] cyclohexane, 1- (3-methoxyphenyl) -1- [4- (2-fluorophenyl) piperazin-1-yl] cyclohexane; methoxyphenyl) -1- [4- (4-fluorophenyl) piperazin-1-yl] cyclohexane, 1- (3-hydroxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-hydroxyphenyl) -1- (4-fluorophenyl) piperazin-1-yl] cyclohexane; dimethoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-methoxyphenyl) -1- (4- phenylpiperazin-1-yl) 4-phenylcyclohexane, 1- (3-n-butoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-methoxyphenyl) -1- (4-phenylpiperazin) -1- yl) -4-methylcyclohexanedichlorhydrate isomer cis and isomer trans, 1- (4-methoxyphenyl) -1- (4- phenylpiperazin-1-yl) cyclohexane, 1- (2-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3,4-methylenedioxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methylcydohexane cis isomer and trans isomer, 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) Cis isomeric cis-4-ethylcyclohexane and trans-isomer, 1- (3-isopropoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methylcydohexane isomer cis and isomer trans, 1- (3-methoxyphenyl) -1- ( Cis-4-phenylpiperazin-1-yl) -3-methylcyclohexane cis isomer and trans isomer, 1- (3-benzyloxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 4- (3-ethoxyphenyl) -4- ( 4-phenylpiperazin-1-yl) tetrahydropyran, 4- (3-ethoxyphenyl) -4- (4-phenylpiperazin-1-yl) tetrahydrothiopyran, 1- (3-methoxymethoxyphenyl) -1- (4-phenylpiperazin-1-yl) Cis-isomeric 4-methylcyclohexane and trans-isomer, 1- (3-ethoxymethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methylcyclohexane isomer c is and trans isomer, 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methoxycydohexane cis isomer and trans isomer,

  VII - Compounds of formula (VI): Ta-Za-NR1a- (R2aCR3a) -CO-Ya- (CH2) na-Ra wherein - na represents 0, 1, 2, 3, 4, or 5; Ra represents a hydrogen atom, a phenyl or naphthyl group optionally mono- or disubstituted with an identical or different substituent chosen from a fluorine, chlorine, bromine or an iodine atom, a cyano or alkyl group, phenyl, hydroxy, alkoxy, dialkylaminoalkoxy, hydroxyphenyl, phenylalkoxy, alkylcarbonyl, amino, alkylamino, dialkylamino, alkylsulfonylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonyloxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonyloxy, alkylsulfonyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl trifluoromethyl, trifluoromethoxy, trifluoro methylthio, aminoalkyl, alkylaminoalkyl, aminocarbonylaminoalkyl, benzoylamino, alkanoylaminoalkyl, alkoxycarbonylaminoalkyl, benzyloxycarbonylaminoalkyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, aminosulfonylamino, alkylaminosulfonylamino, dialkylaminosulphonylamin, cyanamino, amin ocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, aminosulfonylaminoalkyle, alkylaminosulfonylaminoalkyle, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, aminosulfonylalkyl, alkylaminosulfonylalkyl, alkylsulfonyl, aminosulfonyloxy, alkylaminosulfonyloxy, dialkylaminosulfonyloxy or a group cyanoguanidino, an aminophenyl group or aminonaphtyle disubstituted by chlorine or bromine atom, the substituents which may be the same or different, or a hydroxyphenyl or hydroxynaphthyl group disubstituted by a chlorine or bromine atom or by alkyl or alkoxy groups, the sub-components may be identical or different, a diphenylmethyl group, a substituted aminocarbonylalkyl group on the alkyl part with a hydroxyphenylalkyl group or a (2,2-diphenylethyl) aminocarbonylaminophenyl group, a 5-membered heteroaryl group connected by a carbon or nitrogen atom, said heteroaryl comprising an imino group optionally substituted with a (C 1 -C 6) alkyl group or a phenyl group and an oxygen, sulfur or nitrogen atom, or a 6-membered heteroaryl group connected by a carbon atom, said heteroaryl comprising one or two nitrogen atoms, as well as the 5- or 6-membered heteroaromatic rings defined above which constitute a heteroaromatic bicycle with two carbon atoms neighboring the heteroaromatic ring and a 1,4-butadienylene group and further, all the mono- or bicyclic heteroaryl groups mentioned above may be monosubstituted on the carbon skeleton by a fluorine, chlorine or bromine atom, by an alkyl, alkoxy, hydroxy, phenyl, nitro, cyano, carbonyl or alkoxycarbonyl group, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fluoro methyl, difluoromethyl, trifluoromethyl, alkanoyl, aminosulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl, or disubstituted by a fluorine, bromine or chlorine atom, with methyl, methoxy or hydroxy groups, the substituents possibly being identical or different, a phenyl group substituted by a (1,5-dihydro-2,4 (3H) -dioxo-imidazol -3-yl) alkyl or with a [1,2-dihydro-3,5 (4H) -dioxo-3H-1,2,4-triazol-4-yl] alkyl residue, wherein the imidazole or triazole moiety is substituted by 1 or 2 phenyl groups, a cycloalkyl group having from 4 to 8 carbon atoms optionally substituted by a hydroxy, amino, alkylamino or dialkylamino group, the substituents described above not being bonded to the position 1 of the cycloalkyl residue when Y represents an oxygen atom, a group 1 - [[[5,11-dihydro-6 (6H) -oxo-pyrido [2,3-b] [1,4] benzodiazepin-1-yl] carbonyl] methyl] -4-pipéhdinyl or a 3-hydroxy-1-propin-1-yl group, a 2,3-dihydro-1H-isoindol-2-yl group optionally substituted on the nitrogen atom by a diphenylaminocarbonyl group, or a hydroxy group, when Y is an oxy atom gene or a group -NR <4> a- and na represents a number between 2 and 5, - R1a is a hydrogen aroma, a linear or branched (C1-C10) alkyl group, a cycloalkyl group having from 3 to 7 carbon atoms, a phenyl group optionally substituted by a hydroxy or hydroxyalkyl group, or a phenylmethyl group optionally substituted on the phenyl part by a hydroxy or hydroxyalkyl group, -R2a is a non-branched (Cl-O 5) alkyl substituted in the omega position by an amino or alkylamino group protected by a protecting group of the amine group, with a dialkylmino, N-alkylbenzylamino, aminocarbonyl, aminocarbonylamino, aminoethylimine, aminoiminomethyl, amino (hydroxyimino) methyl, amino (alkoxyimino) methyl, amino (nitroimino) methyl group, [ amino (nitroimino) methyl] amino, amino (cyanimino) methyl, [amino (cyanimino) methyl] amino, [(alkylamino) iminomethyl] amino, [(alkylamino) (alkylimino) methyl] amino, [amino (alkylimino) methyl] amino 2-amino-imidazol-1-yl (5-am) ino-4H-1,2,4-triazol-3-yl) amino, (5-amino-4H-1,2,4-triazol-3-yl) methylamino, (3-amino-1,2,4- oxadiazol-5-yl) amino or (5-amino-1,2,4-oxadiazol-3-yl) amino or by imidazol-4-yl, imidazol-2-yl, 1-methyl-imidazol-2 yl, imidazol-2-yl-amino, imidazol-2-yl-methylamino, (4,5-dihydro-1H-imidazol-2-yl) amino optionally substituted on the carbon by one or two methyl groups, or a group phenyl or phenylmethyl optionally substituted on the aromatic rings by cyano, iminomethylamino, cyaniminomethylamino, (methylamino) methyl idenamino, aminoiminomethyl, amino- (hydroxyimino) methyl, amino (alkoxyimino) methyl, hydrazinoiminomethyl, amino (cyanimino) methyl or guanidino or by an imidazol-2-yl, 1-methyl-imidazol-2-yl, 4,5-dihydro-1H-imidazol-2-yl group optionally substituted on the carbon atoms by one or two methyl groups, in which in the aminoiminomethyl, amino (hydroxyimino) methyl and guanidino men In the definition of R2a above, one or more hydrogen atoms connected to the nitrogen atom, independent of each other, may be replaced by alkyl groups or in which two hydrogen atoms connected to different Nitrogen atoms may be replaced by an alkyl bridge having 2 to 4 carbon atoms and for which the hydrogen atom of a group HN <, HN = or H 2 N in the radical R2a may be substituted by an alkoxycarbonyl group having of 2 to 7 carbon atoms, with a phenylalkoxycarbonyl group in which the alkyl is (C1-C6), phenyloxycarbonyl, R15a-CO-O- (R16aCR17a) -O-CO or a group ( R18aO) PO (OR19a) wherein: R15a is a (C1-C15) alkyl group, a (C3-C7) cycloalkyl group, a phenyl group or a phenylalkyl group in which the alkyl is (C1-C3), R16a and R17a, which may be identical or different, represent a hydrogen atom, a (C1-C6) alkyl group, or one of the R16a and R17a residues; have a (C3-C7) cycloalkyl group or a phenyl group, R18a and R19a, which may be identical or different, represent a hydrogen atom, (C1-C4) alkyl groups, benzyl or phenyl groups, Ria is a d hydrogen, a (C1-C7) alkyl group or a (C4-C7) cycloalkyl group, Ta is a hydrogen atom, a phenyl group or a 5-membered heteroaryl group connected by a carbon or nitrogen atom and comprising a nitrogen, oxygen or sulfur atom optionally substituted by an alkyl group, or comprising a nitrogen atom optionally substituted by an alkyl group and an additional sulfur, oxygen or nitrogen atom; or when Za is a bond, Ta is a protecting group of an amino group or the residues (T1aT2aUa) - (CH2) m- or T3,0-, wherein T1a to T3a, the same or different are groups phenyls or 6-membered heteroaryl groups linked by carbon atoms, which follows the s comprise one or two nitrogen atoms, 5-membered heteroaryl groups connected by carbon or nitrogen atoms, comprising a nitrogen atom optionally substituted with an alkyl, sulfur or oxygen group, or comprising a a nitrogen atom optionally substituted by an alkyl group and a nitrogen, sulfur or additional oxygen atom, in which a 1,4-butadienylene bridge may be formed between two carbon atoms neighboring the heteroaryl groups; or 6 members mentioned above in the definition of Ta residues; the bicyclic aromatic or heteroaromatic rings thus formed may also be bonded to a carbon atom of the 1,4-butadienylene group and, moreover, both the phenyl groups, the 5 or 6-membered heteroaryl groups and the bicyclic aromatic or heteroaromatic rings may be mono or disubstituted on the carbon skeleton by fluorine, chlorine, bromine or iodine atoms or by cyano, hydroxy, amino, dimethylamino, diethylamino, N-ethyl-methylamino, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, acetylamino, propionylamino, methanesulfonylamino, methansulfonyloxy, phenyl, phenylmethoxy, 2-phenylethoxy, alkyl, or alkoxy or trisubstituted with an amino or hydroxy group and two chlorine or bromine atoms or with a hydroxy group and two alkyl or alkoxy groups, the substituents being identical or different, and the alkyl and alkoxy moieties mentioned above comprising from 1 to 4 carbon atoms, hydrogen atoms, (C1-C12) alkyl groups, cycloalkyl groups having 3 to 10 carbon atoms, bicycloalkyl or tricycloalkyl groups having 6 to 12 carbon atoms or T1a and T2a together represent a linear chain (C 3 -C 7) alkylene group, Ua is the> CH group, in which the hydrogen atom may be replaced by an alkyl, phenyl, hydroxy, alkoxy, alkanoyloxy, alkoxycarbonyl alkanoylamino group, in which the alkyls or the alkoxys mentioned above may comprise, depending on the case, from 1 to 3 carbon atoms and the alkanoyls mentioned above may comprise 2 or 3 carbon atoms, or the> CHCH 2 group or the nitrogen atom, m represents 0, 1, 2, or 3 or Ta is a group (T1aT2aUa) - (CH2) ma in which T'a, T2a, Ua and ma are as defined above except that the aromatic rings or mono- or bicyclic heteroaromatics mentioned above for T1a and T2a are either by a bond, a -CH2-, -C (CH3) 2-, -CH2CH2-, -CH = CH- or -NHCO- bridge, Ya is an oxygen atom or a group -NR4a, wherein R4a takes again the above-mentioned definition of R1a, the residues of R1a and R4a being identical or different, and Za is a single bond defined by a -CO-, -CH2-, -SO-, or -SO2- group and, unless otherwise stated, the alkyl and alkoxy moieties mentioned above may comprise from 1 to 3 carbon atoms, and the tautomers, diastereomers, enantiomers, mixtures and salts described in WO 94/17035.

  Among these compounds: (R) -N2- (diphenylacetyl) -N- (phenylmethyl) argininamide, (R) -N2- (diphenylacetyl) -N - [(4-methylphenyl) methyl] argininamide, (R) -N- [2- (4-Hydroxyphenyl) ethyl] -N2 - [[5- (2-phenylethoxy) -1H-indol-2-yl] carbonyl] argininamide, N - [(4-aminocarbonylaminophenyl) methyl] -N2- ( diphenylacetyl) argininamide, (R) -N - [(4-hydroxyphenyl) methyl] -N2 - [[5- (2-phenylethoxy) -1H-indol-2-yl] carbonyl] arginamide, (R) -N2 - (diphenylacetyl) -N - [(4-fluorophenyl) methyl] argininamide, (R) -N - [(4-bromophenyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) -N (2-phenylethyl) argininamide, optically active diastereoisomers of N2- (alpha-cyclopentylphenylacetyl) -N - [(4-hydroxyphenyl) methyl] -D-argininamide, N - [[4- (dimethylamino) phenyl] methyl] N, 2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) -N - [[4- (hydroxymethyl) phenyl] methyl] argininamide, (R) -N2- (diphenylacetyl) -N - [[4- ( 1-oxoethyl) phenyl] methyl] argininamide, (R) -N - [(4-chloropyronyl) phenyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) -N - [[4 - [(methylaminocarbonyl) amino] phenyl] methyl] argininamide, (R) -N - [(4) amino-3,5-dichlorphenyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N - [(4-amino-3,5-dichlorphenyl) methyl] -N2 (3,3-diphenyl-1-yl) oxopropyl) argininamide, (R) -N - [(4-amino-3,5-dichlorphenyl) methyl] -N2- (3,4-dichlorobenzoyl) argininamide, N2- (diphenylacetyl) -N- [3- [1- [2- [5,11-Dihydro-6 (6H) -oxopyrido [2,3-b] [1,4] benzo-diazepin-5-yl] -2-oxoethyl] -4-piperidinyl] propyl] argininamide, N2- (diphenylacetyl) -N - [(4-hydroxy-3-methoxyphenyl) methyl] argininamide, N2- (diphenylacetyl) -N - [(3-hydroxy-4-methoxyphenyl) methyl] argininamide, (R, S) N - [(4-amino-3,5-dibromphenyl) methyl] -N6- (aminoiminomethyl) -N2 (diphenylacetyl) lysinamide, N - [(3,5-dimethyl-4-hydroxyphenyl) methyl] -N2- ( diphenylacetyl) argininamide, N - [(1H-benzimidazol-5-yl) methyl] -N2- (diphenylacetyl) argininamide, N2- (diphenylacetyl) -N - [(4-hydroxy-3-methylphenyl) m ethyl] argininamide, N - [[4- (aminocarbonyl) phenyl] methyl] -N2- (diphenylacetyl) argininamide, (R, S) -N6- (aminoiminomethyl) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) ) methyl] lysinamide, (R) -N - [(4-hydroxyphenyl) methyl] -N2- (phenylacetyl) argininamide, N2- (diphenylacetyl) -N - [(1H-indol-5-yl) methyl] arginiamide, (R) -N - [[4- (aminosulfonyl) phenyl] methyl] -N2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) -N - [[4-methoxycarbonyl) phenyl) methyl] argininamide, ( R) -N2- (diphenylacetyl) -N - [(4-pyridinyl) methyl] argininamide, (R) -N - [(4-amino-3,5-dibromphenyl) methyl] -N2- (diphenylacetyl) argininamide, ( R) -N2- (diphenylacetyl) -N - [(2-thienyl) methyl] -N2- (2-naphthoyl) argininamide, (R) -N - [(4-amino-3,5-dichlorphenyl) methyl] - N2- (2-Naphthoyl) argininamide, (R, S) -N5- (4,5-dihydro-1H-imidazol-2-yl) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] ornithinamide, (R, S) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) ornithinamide, (R) -N - [[3- [ (1,2-dihydro-3,5 (4H ) -dioxo-1,2-diphenyl-3H-1,2,4-triazol-4-yl) methyl] phenyl] -N2- (diphenylacetyl) argininamide, N2- (diphenylacetyl) -N - [(3-hydroxyphenyl) methyl] argininamide, (R) -N - [[3 - [(4,5-dihydro-2,4 (3H) -dioxo-5,5-diphenyl-1H-imidazol-3-yl) methyl] phenyl] methyl] -N2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] argininamide, known as BIBP3226, N2- (diphenylacetyl) -N- [2- ( 4-hydroxyphenyl) ethyl] argininamide, N 2 - (diphenylacetyl) - [(4'-hydroxy- [1,1'-biphenyl] -4-yl) methyl] argininamide, N - [[4 - [(1,2- 3,5-dihydro- (4H) -dioxo-1,2-diphenyl-3H-1,2,4-triazol-4-yl) methyl] phenyl] methyl] -N2- (diphenylacetyl) argininamide, N2- (diphenylacetyl) N - [(4-methoxyphenyl) methyl] argininamide, N2- (diphenylacetyl) -N- [2- (4-methoxyphenyl) ethyl] argininamide, N2- (diphenylacetyl) -N- [2- (3-methoxyphenyl) ethyl] ] argininamide, N2- (diphenylacetyl) -N - [(3-methoxylphenyl) methyl] argininamide (R, S) -3- [4- (aminoiminomethyl) phenyl] -N2- (diphenylacetyl) -N- [(4 hydroxyalkyl) methyl] alaninamide, (R, S) -3- [3- (aminoiminomethyl) phenyl] -N2- (diphenylacetyl) -N - [(4-methoxyphenyl) methyl] alaninamide, (R, S) -3- [3- (aminoiminomethyl) phenyl] -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] alaninamide, (R) -N2- [bis- (4-bromophenyl) acetyl] -N - [(4- hydroxyphenyl) methyl] argininamide, (R) -N2- (diphenylacetyl) -N - [(4-ethoxyphenyl) methyl] argininamide, (R) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] -N -methylargininamide, (R, S) -N - [(4-amino-3,5-dibromphenyl) methyl] -3- [3- (aminoiminomethyl) phenyl] -N2- (diphenylacetyl) alaninamine, (R) -N- [(4-hydroxyphenyl) methyl] -N2- (2-naphthoyl) argininamide, (R) -N - [(4-hydroxyphenyl) methyl] -N2- (2-naphthoyl) argininamide, (R) -N2- (2-naphthoyl) arginine 2-diphenyl-2-hydroxyacetyl) -N - [(4-hydroxyphenyl) methyl] argininamide, (R, S) -N2- (diphenylacetyl) -N5- (1H-imidazol-2-yl) -N- [ (4-Methoxyphenyl) methyl] ornithinamide, (R, S) -3- [3- (aminoiminomethyl) phenyl] -N2 - [[(diphenylmethyl) amino] carbonyl] -N - [(4-hydroxyphenyl) m] ethyl] alaninamide, (R, S) -N2- (diphenylacetyl) -N5- (1H-imidazol-2-yl) -N- (phenylmethyl) -omithinamine, (R, S) -N - [(4-amino) -3,5-dichlorphenyl) methyl] -N2- (diphenylacetyl) -N5- (1H-imidazol-2-yl) -ornithithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) -N2- (2-naphthoyl) -ornithinamide, (R, S) -N2 - [[(diphenylmethyl) amino] carbonyl] -N - [(4-hydroxyphenyl) methyl] - N5 (1H-imidazol-2-yl) ornithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) -N2 - [(2-naphthyl) acetyl] ornithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) -N2 - [[(2-naphthyl) amino] carbonyl] ornithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) -N2 - [(1,2,3,4-tetrahydroquinolin-3-yl) carbonyl] ornithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] N5- (1H-imidazol-2-yl) -N2 - [(1,2,3,4-tetrahydroquinolin-2-yl) carbonyl) ] ornithinamide, (R) -N - [(4-aminosulfonylaminophenyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N - [(4-aminophenyl) methyl] -N2- (diphenylacetyl) argi Ninamide, (R) -N - [(6-quinolinyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N2 - [(3,4-dichlorophenyl) acetyl] -N - [(4-hydroxyphenyl) methyl) ] argininamide, (R) -N2- (diphenylacetyl) -N - [[4- (2-hydroxyethyl) phenyl] methyl] argininamide, (R, S) -N5- (3-amino-1,2,4-oxadiazole) 5-yl) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] ornithinamide, (R) -N2 - [(9-fluorenyl) carbonyl] -N - [(4-hydroxyphenyl) methyl] argininamide (R, S) -6- (aminoiminomethyl) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] norleucinamide, (R, S) -3- [4- (4,5-dihydro-1 1H-imidazol-2-yl) phenyl] -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] alaninamide, (R, S) -3- [3- (aminoiminomethyl) phenyl] -N2- (diphenylacetyl) ) -N - [(4-ethoxycarbonyloxyphenyl) methyl] alaninamide, (R, S) -N- [2- (1,2-dihydro-1,2-diphenyl-3,5 (4H) -dioxo-1, 2,4-Triazol-4-yl) ethyl] -N2- (diphenylacetyl) argininamide, (R, S) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] -2-methylargininamide, (R, S) -N2- (diphenylacetyl) -N - [[4- (3-hydroxypropyl) phen yl] methyl] argininamide, (R) -N - [[4 - [(4,5-dihydro-5,5-dimethyl-2,4 (3H) -dioxo-1H-imidazol-3-yl) methyl] phenyl] methyl] -N2- (diphenylacetyl) argininamide.

  VIII - The compounds of formula NH (CH2) (VU) NH in which R "is defined by the formula: R" 2 N- (GH2) n., M,. in which R "1 represents a phenyl group which is unsubstituted or substituted by one or two halogen atoms, a (C1-C3) alkyl group or a pyridinyl ring which is unsubstituted or substituted by one or two halogen atoms, a (C1-C3) group ) alkyl or a (C1-C3) alkoxy group, - R "2 represents a hydrogen atom, a (C1-C3) alkyl group, a phenyl group optionally substituted by one or two halogen atoms or by a group ( C1-C3) alkyl or by a (C1-C3) alkoxy group, a benzyl or heteroaryl group unsubstituted or substituted by one or two halogen atoms or a (C1-C3) alkyl or (C1-C3) alkoxy group n "represents 1, 2, 3 or 4 or wherein R" is defined by the formula: wherein R "3 represents a pyridinyl ring unsubstituted or substituted by one or two halogen atoms, by a group (C1 -C3) alkyl or (C1-C3) alkoxy, R "4 represents a hydrogen atom or a phenyl group optionally substituted with one or two halogen atoms or a (C1-C3) alkyl group or a (C1-C3) alkoxy group, R "represents a hydrogen atom or a methyl or hydroxy group and Z" represents a single bond, an oxygen atom, or a sulfur atom and p "represents 1, 2 or 3 m" represents 1,2 or 3 and R "O represents a hydrogen atom or a methyl group, as well as their pharmaceutically acceptable salts, whose antagonistic NPY effect is described in EP 0 448 765. IX - dihydropyridines of formula

  X R5 (VT I) X R1 wherein - R1x is lower alkyl; R2x and R3x are independently selected from cyano and lower alkyl; -R4x is selected from -002R1 X, cyano and CH3 - R5X is selected from hydrogen, halogen, hydroxyl, lower alkyl, lower alkenyloxy and lower alkoxy; BX is -NH- or a covalent bond; nx represents an integer from 2 to 5 and - ZX is selected from the group consisting of: And solid or dotted lines representing a single or double bond, as well as their addition salts or solvates described in US 5,554,621.

X - Formula compounds

Tyr-Pro-Ser-Lys-Pro-Asp-D-Cys-NH- (CH2) s-CO-Xxx2-Arg-Cys-Tyr-Xxx3-Ala-Leu-Arg-H is-15 Tyr-Xxx4- Asn-Leu-Xxx5-Thr-Arg-Ile-Arg-Tyr-Tc (IX) in which - Xxx2 and Xxx3 are Ser or Ala, - Xxx4 and Xxx5 are Leu, Ile, Met, Nle (Norleucine) or Val - Tc is OH, O (C1-C4) alkyl, NH2 or NH (C1-C4) alkyl, s is an integer from 1 to 11, and their salts, described in EP 0 355 794.

XI - The compounds of formula Zb-Ak, -Bk2-BPk3-Dk4-Ek5-Fk6-Gk7-DP-Thr-Bp'-Glu-BP-K-NH in which k1, k2, k3, k4, k5 , k6 and k7 represent zero or 1, their sum being at least 1, A is Phe or Tyr, B is Pro, Ser, Ala, Gly, Abu, Cys, Pro-Ser, Cys-Ser, Ala-Ser, Gly- Ser, Abu-Ser or Pro-Ala, Abu being 2-aminobutyric acid, BP, BP 'and BP "are amino acids with a basic side chain; D is Pro or Cys; E is NH- (CH2) t-CO, t being 0-10; F is Cys, Abu Gly or Ala; G is Ile-Asn, Leu-Asn, Val-Asn or Asn; DP is the residue of a dipeptide formed by lipophilic amino acids; K is Phe or Tyr; Zb is hydrogen, an amino-protecting group or a benzyl, (C 2 -C 10) acyl or (C 1 -C 5) alkyl group and in which two Cys residues may be linked by a disulfide bridge, as well as their salts, described in DE 3,939,801.

  Among these compounds, those of formula (X) in which BP is Lys or Arg; E is NH- (CH2) t-CO, with t = 1-7; F is Cys or Abu; G is Ile-Asn or Asn; DP is Leu-lie, BP 'and BP ", identical, are Arg, Zb is hydrogen, acetyl or a group where t' is 0, 1 or 2, and their salts are advantageous, the compound of formula

  H-Tyr-Abu-Ser-Lys-Aoc-Abu- Ile-Asn-Leu-I-Thr-Arg-Gln-Arg-Tyr-N H2 where Aoc represents 8-aminooctanoic acid being particularly preferred. XII - Cyclic or linear compounds of formula

  (XI) (Xxxa-Xxxb-Xxxc-Xxxd-Xxx-Xxxf-Xxxg-Xxxh-Xxx; -Xxxi) n

  where Xxxa, Xxxb, Xxxb and Xxxi may not exist, or Xxxa is P1 or Cys; Xxxb is Cys, P1 or one or two amino acids; Xxxg is P1, Cys, Ser, Thr, Ala, or Gly; Xxxg is R1, Cys, Ser, Thr, Ala or Gly; Xxxe is Leu, Ile, Val or Nle; Xxxg is Arg, Lys or His; Hxxg is Arg, Lys, His, Val, Leu, Ile or Nle; Xxxh is Tyr, Phe, Trp, His, Lys or Arg; xxx; represents an NH 2 group or an ester group or one or two amino acids; xxx; is Cys or P2; P1 is hydrogen or a P-CO group where P is hydrogen, a glycosyl, nucleosyl or lipolyl radical or a (C1-C20) alkyl group, optionally containing double bonds and substituents selected from halogens and the group NO2, NH2, OH, sulfo, phospho, carboxy and alkyl; P2 is a group NP12P13 or OP14 in which P12 and P13 represent hydrogen or an alkyl, cycloalkyl, N-glycosyl, N-lipolyl, aralkyl or aryl group; optionally substituted with halogen or with NO2, NH2, OH, sulfo, phospho, carboxy or alkyl; and P14 represents hydrogen or an alkyl, cycloalkyl, aralkyl, -O-glycosyl, -O-lipolyl, aralkyl or aryl group, optionally substituted by a halogen or a NO2, NH2, OH, sulfo, phospho, carboxy or alkyl, with the limitation that when Xxxb does not exist or represents Cys or P1, then Xxxa is non-existent, when Xxxd is Cys or P1, then Xxxc is non-existent, when Xxx; is NH2 or an ester, then Xxx; is nonexistent. These compounds are described in WO 93/12139, especially the compound Ser-Ala-Leu-Arg-His-Tyr-NH2.

  XIII - Compounds of formula H-Tyr-Pro $ er-Ly-Pro-Asp-sn-Pro-1-Gln- (XI) Asp-Ala-Pro-Ala-Glu-A p-Xxx6-Ala-Arg- Tyr-TyrS + srwA (α-Leu-Arg-Hs-Tyr-1le-Asn-Leu-IJe-Thr-Arg-Xxxrx xx8.l- (CH2) P3 in which z is 0,1 or 2. Xxx6 is Met or Leu; Xxx7 is Glu, (R) -Glu, Pro or (R) -Pro; Xxx8 is Arg, (R) -Arg or (R, S) -Arg; L1 is O or NP ', P'; being H or alkyl, and P3 is phenyl or naphthyl unsubstituted or substituted by one or two of F, Cl, Br, alkyl, phenyl, OH, (phenyl) alkoxy, alkylcarbonyl, NH2 (optionally substituted by one or two alkyls). ), alkylsufonyl, alkyl- or alkoxycarbonylamino, COOH, alkoxycarbonyl, NH2CO (optionally substituted by one or two alkyls), alkylcarbonyloxy, alkylsulfonyloxy, CH2OH, 1- or 2-hydroxyethyl, (alkyl) aminosulfonyl, cyanamino, aminocarbonylamino (optionally substituted by one or two alkyls) or NH2C (= N.CN) NH; a 5 member aromatic heterocycle containing oxygen, sulfur or nitrogen, an imi group no or an imino group containing oxygen, sulfur or nitrogen; a 6-membered aromatic heterocycle with one or two nitrogen atoms; said heterocyclic rings being C-substituted by (C 1 -C 6) alkyl or by phenylalkyl and optionally fused to benzene and optionally also substituted with either F, Cl, Br, (C 1 -C 6) alkyl, alkoxy, OH, phenyl, NO 2 , NH215 (optionally substituted with one or two alkyls or with an alkanoyl), CN, COOH, alkoxycarbonyl, NH2CO (optionally substituted with one or two alkyls), CH2F, CHF2, CF3, alkanoyl or NH2SO2 (optionally substituted with one or two alkyls). ) or two F, Cl, Br, methyl, methoxy or OH; a phenyl group substituted with a [1,5-dihydro-2,4- (3H) -dioxoimidazol-3-yl] alkyl group or a [3,5-dihydro-4H-dioxo-3H-1 group, 2,4-triazol-4-yl] alkyl of which the imidazole and triazole groups may be substituted by one or two phenyls; alkyl and alkoxy groups containing from 1 to 3 carbon atoms, and their salts. These compounds are illustrated in DE 4 311 756.

  XIV - The NPY-antagonists prepared according to WO 94/00486, JP 06-116284, JP 07-267988, DE 3,811,193, US 5,328,899 and WO 95/00161, such as the compound (X111) CH3CC -D-Cys-Leu -It-Thr-Arg • Cy.Arg-Tyr-N described in JP 06-116284 and the compound (XIV) I-Cys-Pro-Cys-Tyr-Arg-Leu-Arg-Tyr-NH2-Cys- Pro-Cys-Tyr-Arg-Leu-Arg-Tyr-N H2 described in WO 94/00486.

  XV - The extracts with NPY-antagonist activity obtained by extraction of a spongier, Orina sp. Gray (or Gellius sp.), Especially the indole compounds described in J. Nat. Products, 1994, 57, 1294-1299 and ibid 1995, 58, 8, 1254-1260, or mixtures thereof, more particularly gelliusin A, gelliusin B, 2- [5-hydroxy-3- (2- aminoethyl)] indol-2-yl-6-bromo-3-indoleethanamine, 2- [6-bromo-3- (2-aminoethyl)] indol-2-yl-6-bromo-3-indoleethanamine, their salts and their mixtures.

  XVI-fermentations extracts of strains of Aspergillus, for example of Aspergillus piger with NPY-antagonist activity, in particular the compound known by the name of code (XIII) (XIV) BMS-192548, preparable by extraction of the medium of cultivation of Aspergillus niger WB 2346, as described in J. Antibiotics, 1995, 48, 10, 1055-1059, having the formula (XV) (XV) H3 CH3 3 OH 0

  XVII - The products, in particular the extracts obtained by fermentation of Actinomycetaceae strains, having an NPY-antagonist activity, these strains and their culture are described in EP 0 838 217 (11332 deposited at the C.N.C.M. of the Pasteur Institute).

  Those skilled in the art will be able to adjust the NPY antagonist compound concentration according to the desired effect, namely the protection and / or care of weakened, damaged or sensitive lips, and the activity of said antagonist. This concentration may be between 10-8 and 10%, better 10-6 and 5%, better 10-4 and 2%.

  Advantageously, said compound used according to the invention may be incorporated into a system allowing its release at the lips, after application of the composition thereon.

  In particular, said compound may be adsorbed or incorporated in particle structures having a size ranging from 1 nm to a few m (10 m), such as, for example, microcapsules, microparticles, ionic-type vesicular dispersions (liposomes or oleosomes) and or nonionic (niosomes) and / or nanosphere dispersions. These particles may be advantageously porous and consist of silicates or aluminosilicates. Examples of such formulations are described in particular in patents EP 0 199 636, EP 0 375 520, EP 0 447 318, EP 0 557 489, WO 97/12602, EP 1 151 741 or US 5,914,126. By way of example, the microspheres may be prepared according to the method described in the patent application EP 0 375 520. The nanospheres may be in the form of an aqueous suspension and may be prepared according to the methods described in the FR 00 patent applications. 15686 and FR 01 01438. The oleosomes consist of an oil-in-water emulsion formed by oily globules provided with a lamellar liquid crystal coating dispersed in an aqueous phase (see patent applications EP 0 641 557 and EP 0 705 593). The agent according to the invention may also be encapsulated in nanocapsules consisting of a lamellar coating obtained from a silicone surfactant such as described in the patent application EP 0 780 115; the nanocapsules may also be prepared based on water-dispersible sulfonic polyesters according to, for example, the technique described in the patent application FR 01 13337.

  The compositions according to the invention may also comprise at least one agent chosen from solvents, oils, waxes, pastes, gums, fillers, dyestuffs, cosmetic active agents, thickeners, surfactants, moisturizers, softeners, sequestering agents, perfumes, neutralizers, preservatives, antioxidants, bactericides, trace elements, odor absorbers and mixtures thereof. The amounts of these different agents are those conventionally used in the field under consideration, for example from 0.01 to 20% of the total weight of the composition.

  The composition may be in any galenical form normally used for topical application and especially in anhydrous form, in the form of an oily or aqueous solution, an oily or aqueous gel, an oil-in-water or water emulsion. - in-oil, a multiple emulsion, an oil dispersion in water through vesicles located at the oil / water interface. The composition of the invention may be in the form of a liquid, a solid or semisolid, in particular a product cast in a stick or a dish, a stick, a paste or a more or less fluid cream.

  The composition of the invention can be obtained according to the preparation methods conventionally used in cosmetics.

  By physiologically acceptable medium is meant a medium compatible with the lips of humans.

  The physiologically acceptable medium will be adapted to the nature of the support on which the composition is to be applied and to the form in which the composition is intended to be packaged, especially solid or fluid at ambient temperature and atmospheric pressure.

  The composition according to the invention may comprise an aqueous cosmetic medium and / or a fatty phase. The composition may comprise water or a mixture of water and hydrophilic organic solvents such as alcohols and in particular linear or branched lower monoalcohols having from 2 to 5 carbon atoms, such as ethanol, isopropanol or n-butanol. propanol, polyols such as glycerine, diglycerine, propylene glycol, sorbitol, penthylene glycol, polyethylene glycols. The hydrophilic phase may further contain 02 ethers and hydrophilic 02-04 aldehydes. The water or the mixture of water and hydrophilic organic solvents may be present in the composition according to the invention, or one of the base and / or surface compositions, in a content ranging from 0% to 90%. 0 (in particular 0.1% to 90%) by weight, relative to the total weight of the composition, and preferably from 0% to 60% by weight (in particular 0.1% to 60% by weight).

  The composition may also comprise a fatty phase, especially consisting of fatty substances that are liquid at room temperature (generally 25 ° C.) and / or fatty substances that are solid at ambient temperature, such as waxes, pasty fatty substances, gums and mixtures thereof. This fatty phase may, in addition, contain lipophilic organic solvents.

  As liquid fatty substances at room temperature, often called oils, which can be used in the invention, mention may be made of: vegetable hydrocarbon-based oils such as liquid triglycerides of fatty acids with 4 to 10 carbon atoms, such as triglycerides of heptanoic or octanoic acids or sunflower, corn, soybean, grape seed, sesame, apricot, macadamia, castor oil, avocado oil, caprylic / capric acid triglycerides, jojoba oil, shea butter; linear or branched hydrocarbons of mineral or synthetic origin, such as liquid paraffins and derivatives thereof, petroleum jelly, polydecenes, hydrogenated polyisobutene such as parleam; esters and synthetic ethers, in particular of fatty acids, for example purcellin oil, isopropyl myristate, 2-ethylhexyl palmitate, octyl-2-dodecyl stearate, erucate octyl-2-dodecyl, isostearyl isostearate; hydroxylated esters such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates, decanoates of fatty alcohols; polyol esters such as propylene glycol dioctanoate, neopentyl glycol diheptanoate, diethylene glycol diisononanoate; and pentaerythritol esters; fatty alcohols having 12 to 26 carbon atoms such as octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleyl alcohol; partially hydrocarbon and / or silicone fluorinated oils; silicone oils, such as volatile or nonvolatile polymethylsiloxanes (PDMS), linear or cyclic, liquid or pasty at room temperature, such as cyclomethicones, dimethicones, optionally comprising a phenyl group, such as phenyl trimethicones, phenyltrimethylsiloxydiphenylsiloxanes or diphenylmethyldimethyltrisiloxanes, diphenyl dimethicones, phenyl dimethicones, polymethylphenyl siloxanes; their mixtures. These oils may be present in a content ranging from 0.01 to 90%, and better still from 0.1 to 85% by weight, relative to the total weight of the composition.

  The composition of the invention may further advantageously comprise a solid or pasty fatty substance at room temperature, such as gums or waxes.

  The waxes may be hydrocarbon-based, fluorinated and / or silicone-based and may be of vegetable, mineral, animal and / or synthetic origin. In particular, the waxes may have a melting temperature of greater than 25 ° C. and better still greater than 45 ° C. As wax which can be used in the composition of the invention, mention may be made of beeswax, Carnauba wax or Candelilla wax, paraffin, microcrystalline waxes, ceresin or ozokerite; synthetic waxes such as polyethylene or Fischer Tropsch waxes, silicone waxes such as alkyl or alkoxy dimethicone having from 16 to 45 carbon atoms.

  The gums that can be used are generally high molecular weight polydimethylsiloxanes (PDMS) or cellulose gums or polysaccharides and the pasty substances are generally hydrocarbon compounds such as lanolines and their derivatives or else PDMSs.

  By pasty is meant a lipophilic fat compound, reversible solid / liquid state change, having at 23 C a liquid fraction and a solid fraction. Paste is also understood to mean vinyl polylaurate. The pasty compounds are advantageously chosen from: lanolin and its derivatives, fluorinated compounds which are polymeric or non-polymeric, silicone compounds which are polymeric or non-polymeric, vinyl polymers, in particular: homopolymers of olefins, copolymers of olefins - homopolymers and copolymers of hydrogenated dienes - linear or branched oligomers, homo or copolymers of alkyl (meth) acrylates preferably having a C8-C30 alkyl group - homo and copolymeric oligomers of vinyl esters having groups C8-C30 alkyls - homo- and copolymer oligomers of vinyl ethers having C8-C30 alkyl groups, - the liposoluble polyethers resulting from the polyetherification between one or more C2-C100 diols, preferably C2-C50 diols, - the esters , and their mixtures.

  Among the liposoluble polyethers, copolymers of ethylene oxide and / or propylene oxide with long-chain C 6 -C 30 alkylene oxides are preferred, more preferably such as the weight ratio of ethylene oxide. and / or propylene oxide with alkylene oxides in the copolymer is from 5:95 to 70:30. In this family, mention will in particular be made of copolymers such as long-chain alkylene oxides are arranged in blocks having an average molecular weight of 1,000 to 10,000, for example a polyoxyethylene / polydodecyl glycol block copolymer such as dodecanediol ethers (22 mol) and polyethylene glycol (45 EO) marketed under the trademark ELFACOS ST9 by Akzo Nobel.

  Among the pasty esters, the following are particularly preferred: esters of an oligomeric glycerol, in particular the diglycerol esters, in particular the adipic acid and glycerol condensates, for which part of the hydroxyl groups of the glycerols have reacted with a mixture of fatty acids such as stearic acid, capric acid, stearic acid and isostearic acid and 12-hydroxystearic acid, such as those marketed under the trademark Softisan 649 by the company Sasol, arachidyl propionate sold under the name Waxenol 801 by Alzo, phytosterol esters, non-crosslinked polyesters resulting from the polycondensation between a linear or branched C 4 -C 50 diacid or polycarboxylic acid and a C2-C2 diol or polyol; 050, different from the polyester described above, the ester aliphatic esters resulting from the esterification of an aliphatic hydroxycarboxylic acid ester by a monocarboxylic acid aliphatic than; and their mixtures, such as the ester resulting from the esterification reaction of hydrogenated castor oil with isostearic acid in proportions 1 to 1 (1/1) or hydrogenated castor oil monoisostearate, the ester resulting from the esterification reaction of hydrogenated castor oil with isostearic acid in proportions 1 to 2 (1/2) or hydrogenated castor oil diisostearate, the ester resulting from the esterification reaction hydrogenated castor oil with isostearic acid in proportions 1 to 3 (1/3) or hydrogenated castor oil triisostearate, and mixtures thereof.

  Among the pasty compounds of vegetable origin, a mixture of soybean sterols and pentaerythritol oxyethylenated (5OE) oxypropylenated (5 OP), marketed under the reference Lanolide by the company VEVY, will preferably be chosen.

  The pasty compound is preferably 1 to 99%, more preferably 1 to 60%, more preferably 2 to 30% and more preferably 5 to 15% by weight of the composition. The nature and quantity of the solid bodies depend on the mechanical properties and textures sought. The composition may contain from 0 to 50% by weight of waxes, relative to the total weight of the composition and better still from 1 to 30% by weight.

  By fillers, it is necessary to include particles of any form, colorless or white, mineral or synthetic, insoluble in the medium of the composition regardless of the temperature at which the composition is manufactured. These fillers serve in particular to modify the rheology or the texture of the composition. The fillers may be inorganic or organic in any form, platelet-shaped, spherical or oblong, irrespective of the crystallographic form (for example, sheet, cubic, hexagonal, orthorhombic, etc.). Mention may be made of talc, mica, silica, kaolin, polyamide (nylon) powders (Orgasol from Atochem), poly-13-alanine and polyethylene, and tetrafluoroethylene polymer powders (Teflon). lauroyl-lysine, starch, boron nitride, polymeric hollow microspheres such as those of polyvinylidene chloride / acrylonitrile such as Expancel (Nobel Industrie), copolymers of acrylic acid (Polytrap 603 from Dow) Corning) and silicone resin microbeads (Toshiba Tospearls, for example), elastomeric polyorganosiloxane particles, precipitated calcium carbonate, magnesium carbonate and magnesium carbonate, hydroxyapatite, hollow silica microspheres (Silica Beads from Maprecos), microcapsules of glass or ceramic, metal soaps derived from organic carboxylic acids having from 8 to 22 carbon atoms, preferably from 12 to 18 carbon atoms, for example zinc, magnesium or lithium stearate, zinc laurate, magnesium myristate, Polypore L 200 (Chemdal Corporation). Mention may also be made of silica-based fillers such as Aerosil 200 and Aerosil 300; Sunsphare L-31, Sunphare H-31 marketed by Asahi Glass; Chemicelen marketed by Asahi Chemical; silica and titanium dioxide composites such as the TSG series marketed by Nippon Sheet Glass. Finally, mention may be made of polyurethane powders, in particular crosslinked polyurethane powders comprising a copolymer, said copolymer comprising trimethylol hexyl lactone. In particular, it may be a hexamethylene diisocyanate / trimethylol hexyllactone polymer. Such particles are in particular commercially available, for example under the name PLASTIC POWDER D-400 or PLASTIC POWDER D-800 from TOSHIKI. The filler content may range from 0.01% to 50% by weight, preferably ranging from 0.01% to 30% by weight relative to the total weight of the composition.

  For the purposes of the present invention, the term "dyestuff" means a compound capable of producing an optical effect when it is formulated in sufficient quantity in a suitable cosmetic medium. The dyestuffs may be present in the composition in a content ranging from 0.01% to 50% by weight, relative to the weight of the composition, preferably from 0.1% to 30% by weight.

  The dyestuff may especially be chosen from dyes, pigments, pearlescent agents and their mixtures. The dyes are preferably fat-soluble dyes, although the water-soluble dyes may be used. Liposoluble dyes are, for example, Sudan Red, D & C Red 17, D & C Green 6, 13-carotene, soybean oil, Sudan Brown, D & C Yellow 11, D & C Violet 2, D & C orange 5, yellow quinoline, annatto. They may represent from 0 to 20% of the weight of the composition and better still from 0.1 to 6%. When used, the water-soluble dyes include beetroot juice, methylene blue and may represent from 0.1 to 6% by weight of the composition.

  The pigments may be chosen from inorganic pigments, organic pigments, and composite pigments (that is to say pigments based on mineral and / or organic materials). By pigments, it is necessary to include particles of any shape, with an optical effect, mineral or synthetic, insoluble in the medium of the composition regardless of the temperature at which the composition is manufactured.

  The inorganic pigments may be chosen from metal oxide pigments, titanium dioxide coated mica, bismuth oxychloride coated mica, iron oxide coated titanium mica, ferric blue coated mica-titanium, titanium mica coated with chromium oxide, and mixtures thereof. The metal oxide pigments are, for example, iron oxides, titanium dioxide, zinc oxides, zirconium oxides, cerium oxides, and mixtures thereof. The inorganic pigments are preferably metal oxide pigments. The pigments may be present in the composition in a content ranging from 0.01% to 25% by weight, relative to the total weight of the composition, and preferably ranging from 1% to 12% by weight, and preferably ranging from 3% to 8% by weight. % in weight.

  The organic pigments can be chosen from the pigments and lakes cited in the International Cosmetic Ingredient Dictionary and Handbook, Edition 1997, pages 371 to 386 and 524 to 528, published by The Cosmetic, Toiletry, and Fragrance Association, the content of which is incorporated in this application for reference.

  The nacres may be chosen, for example, from mica coated with titanium oxide, iron oxide, natural pigment or bismuth oxychloride such as colored titanium mica. The NPY antagonist compounds may also be combined in the compositions according to the invention have hydrophilic or lipophilic cosmetic active ingredients, in particular for the purpose of enhancing the appearance of the lips. This active agent may be chosen in particular from: - agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation (eg collagen synthesis, elastin, etc.), - moisturizing agents, - anti-pollution or anti-agents -radical, - soothing agents, - healing agents, - UV filters.

  Agents stimulating the synthesis of matrix macromolecules Dermal cells, in particular fibroblasts, produce molecules of collagen, elastin and glycoproteins. These molecules confer volume and density to the lips and their outline, as well as their firmness. With the effect of age or even under the effect of UV rays, there is a notable decrease in these molecules and a degradation of collagen and elastin fibers under the effect of collagenase or elastase. This degradation or decrease in the production of these molecules induces a loss of firmness of the lips and their outline, causing in particular the appearance of wrinkles. Among the active agents stimulating the macromolecules of the dermis or preventing their degradation, there may be mentioned those which act: either on the synthesis of collagen, such as extracts of Centella asiatica; asiaticosides and derivatives; ascorbic acid or vitamin C and its derivatives, such as its salts or its esters, in particular 5,6-di-O-dimethylsilylascorbate (sold by Exsymol under the reference PRO-AA), the potassium salt of the dl- alpha-tocopheryl-dl-ascorbyl phosphate (sold by Senju Pharmaceutical under the reference SEPIVITAL EPC), magnesium ascorbyl phosphate, sodium ascorbyl phosphate (sold by Roche under the reference Stay-C 50) and ascorbyl glucoside ( sold by Hayashibara); synthetic peptides such as iamin, biopeptide CL or palmitoyloligopeptide marketed by SEDERMA; peptides extracted from plants, such as the soy hydrolyzate marketed by COLETICA under the trade name Phytokine; plant hormones such as auxins and lignans; palmitoyl pentapeptide lysine-threonine-threonine-lysine-serine sold in particular under the name MATRIXYL by SEDERMA: dimethyl amino ethanol; Bupleurum Chinensis ricehome extracts, such as those sold under the names PLEURIMINCYL, LIPOCARE by SEDERMA; hydrolyzates of wheat protein acylated in particular by a palmitoyl group, such as that sold under the name LIPACID PVB by SEPPIC; creatine; coenzyme Q10; or on the synthesis of elastin, such as the extract of Saccharomyces cerivisiae sold by LSN under the trade name Cytovitin; and the algae extract Macrocystis pyrifera marketed by SECMA under the trade name Kelpadelie; melibiose; soy protein; or on the synthesis of glycosaminoglycans, such as the product of fermentation of milk with Lactobacillus vulgaris, marketed by BROOKS under the trade name Biomin yogourth; the extract of the brown alga Padina pavonica sold by Alban Müller under the trade name HSP3; and the extract of Saccharomyces cerevisiae available in particular from SILAB under the trade name Firmalift or from LSN under the trade name Cytovitin; C-glycosides and their derivatives as described in EP 1 345 919; or on the synthesis of fibronectin, such as the Salina zooplankton extract marketed by SEPORGA under the trade name GP4G; yeast extract available in particular from ALBAN MÜLLER under the trademark Drieline; and the palmitoyl pentapeptide sold by SEDERMA under the trademark Matrixil; - Or on the inhibition of metalloproteinases (matrix metalloproteinases or MMP) such as more particularly the MMP 1, 2, 3, 9. There may be mentioned: retinoids and derivatives, oligopeptides and lipopeptides, lipoamino acids, malt extract marketed by Coletica under the trade name Collalift; extracts of blueberry or Rosmarinus officinale; lycopene; isoflavones, their derivatives or plant extracts containing them, in particular extracts of soya (marketed for example by ICHIMARU PHARCOS under the trade name Flavosterone SB), red clover, flax, kakkon or sage; or on the inhibition of serine proteases such as leukocyte elastase or cathepsin G. Mention may be made of: the peptide extract of leguminous seeds (Pisum sativum) sold by LSN under the trademark Parelastyl; heparinoids; and pseudodipeptides such as {2- [acetyl- (3-trifluoromethylphenyl) -amino] -3-methyl-butyrylamino} acetic acid and its derivatives.

  Among the active ingredients stimulating fillagrine and keratins, mention may be made in particular of the lupine extract marketed by SILAB under the trademark Structurine; the extract of beech buds Fagus sylvatica marketed by Gattefosse under the trade name Gatuline; and Salina zooplankton extract marketed by SEPORGA under the trade name GP4G.

  Preferably, the agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation are chosen from extracts of Centella asiatica, ascorbic acid and its derivatives, peptides extracted from plants, such as commercialized soy hydrolyzate by COLETICA under the trade name Phytokine, the extract of Saccharomyces cerivisiae sold by LSN under the trade name Cytovitin; the extract of the brown alga Padina pavonica sold by Alban Müller under the trade name HSP3; retinoids and derivatives; rosemary extracts; the peptide extract of leguminous seeds (Pisum sativum) marketed by LSN under the trademark Parelastyl; {2- [acetyl- (3-trifluoromethyl-phenyl) -amino] -3-methyl-butyrylamino} acetic acid and its analogs as described in EP 1 292 608, lupine extract; and their mixtures.

  Moisturizing agents By "moisturizing agent" is meant: - either a compound acting on the barrier function, with a view to maintaining the hydration of the stratum corneum, or an occlusive compound. There may be mentioned ceramides, sphingoid-based compounds, lecithins, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols (stigmasterol, 13-sitosterol, campesterol), essential fatty acids, 1-2 diacylglycerol, 4-chromanone, pentacyclic triterpenes such as ursolic acid, petrolatum and lanolin; or a compound directly increasing the water content of the stratum corneum, such as thralose and its derivatives, hyaluronic acid and its derivatives, glycerol, pentanediol, sodium pidolate, serine, xylitol, lactate sodium, glycerol polyacrylate, ectoin and its derivatives, chitosan, oligo- and polysaccharides such as the product marketed under the reference Pentavitin, honey, alginates (in particular the product Sobalg PH 154 marketed by Grindsted), carbonates cyclic N-lauroyl pyrrolidone carboxylic acid or its salts, especially the sodium salt sold under the reference Nalidone, and Na-benzoyl-L-arginine; or a compound that activates the sebaceous glands, such as steroid derivatives (including DHEA, its 7-oxidized and / or 17-alkylated derivatives and sapogenins), methyl dihydrojasmonate, and vitamin D and its derivatives. These compounds may represent from 0.001 to 30%, and preferably from 0.01 to 20%, of the total weight of the composition according to the invention.

  Anti-pollution or anti-radical agent By the term "anti-pollution agent" is meant any compound capable of trapping ozone, mono- or polycyclic aromatic compounds such as benzopyrene and / or heavy metals such as cobalt, mercury, cadmium and / or nickel. By "anti-radical agent" is meant any compound capable of trapping free radicals.

  As ozone-trapping agents that may be used in the composition according to the invention, mention may be made in particular of vitamin C and its derivatives including ascorbyl glucoside; phenols and polyphenols, in particular tannins, ellagic acid and tannic acid; epigallocatechin and natural extracts containing it; olive leaf extracts; tea extracts, especially green tea; anthocyanins; rosemary extracts; phenolic acids, in particular chorogenic acid; stilbenes, in particular resveratrol; sulfur-containing amino acid derivatives, in particular S-carboxymethylcysteine; ergothioneine; N-acetylcysteine; chelating agents such as N, N'-bis- (3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; carotenoids such as crocetin; and various raw materials such as the mixture of arginine, histidine ribonucleate, mannitol, adenosinetriphosphate, pyridoxine, phenylalanine, tyrosine and hydrolysed RNA marketed by the Serobiological Laboratories under the trade name CPP LS 2633-12F, the water-soluble fraction of corn marketed by the company SOLABIA under the trade name Phytovityl, the mixture of fumitory extract and lemon extract marketed under the name Unicotrozon C-49 by Induchem, and the mixture of extracts of ginseng, apple, peach, wheat and barley sold by PROVITAL under the trade name Pronalen Bioprotect.

  As scavengers for mono- or polycyclic aromatic compounds that can be used in the composition according to the invention, mention may be made in particular of tannins such as ellagic acid; indole derivatives, in particular indol-3-carbinol; tea extracts especially green tea, extracts of water hyacinth or eichornia crassipes; and the water soluble fraction of corn marketed by SOLABIA under the trade name Phytovityl.

  Finally, as scavengers for heavy metals that may be used in the composition according to the invention, there may be mentioned in particular chelating agents such as EDTA, the pentasodium salt of ethylenediamine tetramethylene phosphonic acid, and N, N'-bis- ( 3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters phytic acid; chitosan derivatives; tea extracts, especially green tea tannins such as ellagic acid; sulfur-containing amino acids such as cysteine; water hyacinth (Eichornia crassipes) extracts; and the water soluble fraction of corn marketed by SOLABIA under the trade name Phytovityl.

  The anti-radical agents that can be used in the composition according to the invention comprise, in addition to certain anti-pollution agents mentioned above, vitamin E and its derivatives such as tocopheryl acetate; bioflavonoids; coenzyme Q10 or ubiquinone; certain enzymes such as catalase, superoxide dismutase and wheat germ extracts containing it, lactoperoxidase, glutathione peroxidase and quinone reductases; glutathione; benzylidene camphor; benzylcyclanones substituted naphthalenones; pidolates; phytantriol; gamma-oryzanol; guanosine; lignans; and melatonin.

  Soothing agents As soothing agents that can be used in the composition according to the invention, mention may be made of pentacyclic triterpenes and plant extracts (eg Glycyrrhiza glabra) containing them, such as 13-glycyrrhetinic acid and its salts and / or derivatives thereof (1). glycyrrhetinic acid monoglucuronide, stearyl glycyrrhetinate, 3-stearoyloxy glycyrrhetic acid), ursolic acid and its salts, oleanolic acid and its salts, betulinic acid and its salts, plant extracts such as Paeonia suffruticosa and / or lactiflora, Laminaria saccharina, Boswellia serrata, Centipeda cunnighami, Helianthus annuus, Linum usitatissimum, Cola nitida, Epilobium Angustifolium, Aloe vera, Bacopa monieri, salts of salicylic acid and in particular zinc salicylate, oil canola, bisabolol and chamomile extracts, allantoin, sepivital EPC (vitamin E and C diesterphosphoric acid) from Seppic, unsaturated omega 3 oils such as s of muscat rose, cassis, ecchium, or fish, plankton extracts, capryloyl glycine, Seppicalm VG (sodium palmitoylproline and nymphea alba) from Seppic, tocotrienols, piperonal, clove extract , phytosterols, cortisone, hydrocortisone, indomethacin and beta methasone. Thus, that the substance P or CGRP antagonists described in EP 0 680 749 and EP 0 723 774, the thermal waters of the Vichy basin or Roche Posay, the extracts of Vitreoscilla filiformis described in the patent applications FR 2 279 382, EP0765667, EP 0 876 813 and EP 1 531 158.

  Healing Agents Examples of cicatrizing agents include the fern leaf extract marketed under the reference Mamaku Vital Essence by Lucas Meyer, rice peptides obtained by hydrolysis of rice proteins marketed under the name Nutripeptide by Silab.

  UV Filters The compositions according to the invention may further comprise at least one organic photoprotective agent and / or at least one active inorganic photoprotective agent in the UVA and / or UVB (absorbers), which are water-soluble or fat-soluble or insoluble in cosmetic solvents commonly used. The compositions in accordance with the invention may comprise, in addition, other additional organic UV or inorganic UV screening agents active in water-soluble or fat-soluble UVA and / or UVB or insoluble in the cosmetic solvents commonly used. The complementary organic screening agents are chosen in particular from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives, camphor derivatives; triazine derivatives other than those of the invention such as those described in patent applications US 4367390, EP863145, EP517104, EP570838, EP796851, EP775698, EP878469, EP933376, EP507691, EP507692, EP790243, EP944624; benzophenone derivatives; 13,13-diphenylacrylate derivatives; benzotriazole derivatives; benzalmalonate derivatives; benzimidazole derivatives; imidazolines; bis-benzoazolyl derivatives as described in patents EP669323 and US 2,463,264; p-aminobenzoic acid derivatives (PABA); methylene bis- (hydroxyphenylbenzotriazole) derivatives as described in US 5,237,071, US 5,166,355, GB2303549, DE 197 26 184 and EP893119; filter polymers and silicone filters such as those described in particular in the application WO-93/04665; dimers derived from α-alkylstyrene such as those described in patent application DE19855649; 4,4-diarylbutadienes as described in Applications EP0967200, DE19746654, DE19755649, EP-A-1008586, EP1133980 and EP133981 and mixtures thereof. As examples of additional organic screening agents, mention may be made of those referred to below under their INCI name: Derivatives of para-aminobenzoic acid: PABA, Ethyl PABA, Ethyl Dihydroxypropyl PABA, Ethylhexyl Dimethyl PABA sold in particular under the name Escalol 507 by ISP, Glyceryl PABA, PEG-25 PABA sold under the name UVINUL P25 by BASF, - Salicylic derivatives: Homosalate sold under the name Eusolex HMS by Rona / EM Industries, Ethylhexyl salicylate sold under the name NEO HELIOPAN OS by HAARMANN and REIMER, Dipropylene glycol Salicylate sold under the name DIPSAL by SCHER, TEA Salicylate, sold under the name NEO HELIOPAN TS by HAARMANN and REIMER, Derivatives of dibenzoylmethane: Butyl Methoxydibenzoylmethane sold in particular under the trade name PARSOL 1789 by HOFFMANN LA ROCHE, Isopropyl Dibenzoylmethane, cinnamic derivatives : Ethylhexyl methoxycinnamate sold in particular under the trade name PARSOL MCX by HOFFMANN LA ROCHE, Isopropyl Meth oxy cinnamate, Isoamyl Methoxy cinnamate sold under the trade name NEO HELIOPAN E 1000 by HAARMANN and REIMER, DEA Methoxycinnamate, Diisopropyl Methylcinnamate, Glyceryl Ethylhexanoate Dimethoxycinnamate -Derivatives of 13,13'-diphenylacrylate: Octocrylene sold in particular under the trade name UVINUL N539 by BASF , Etocrylene, sold in particular under the trade name UVINUL N35 by BASF, - Derivatives of benzophenone: Benzophenone-1 sold under the trade name UVINUL 400 by BASF, Benzophenone-2 sold under the trade name UVINUL D50 by BASF, Benzophenone-3 or Oxybenzone, sold under the trade name UVINUL M40 by BASF, Benzophenone-4 sold under the trade name UVINUL MS40 by BASF, Benzophenone-5, Benzophenone-6 sold under the trade name Helisorb 11 by Norquay, Benzophenone-8 sold under the trade name Spectra- Sorb UV-24 by American Cyanamid, Benzophenone-9 sold under the trade name UVINUL DS-49 by BASF, Benzophenone-12, Di ethylamino Hydroxybenzoyl Hexyl Benzoate sold under the trade name UVINUL A PLUS by BASF, - Derivatives of benzylidene camphor: 3-Benzylidene camphor manufactured under the name 35 MEXORYL SD by CHIMEX, 4-Methylbenzylidene camphor sold under the name EUSOLEX 6300 by MERCK, Benzylidene Camphor Sulfonic Acid manufactured under the name MEXORYL SL by CHIMEX, Camphor Benzalkonium Methosulfate manufactured under the name Mexoryl SO by Chimex, Terephthalylidene Dicamphor Sulfonic Acid manufactured under the name MEXORYL SX by Chimex, Polyacrylamidomethyl Benzylidene Camphor manufactured under the name MEXORYL SW by CHIMEX, - Derivatives phenyl benzimidazole: Phenylbenzimidazole Sulfonic Acid sold in particular under the trade name Eusolex 232 by Merck, Disodium Phenyl Dibenzimidazole Tetrasulfonate sold under the trade name NEO HELIOPAN AP by HAARMANN and REIMER, - Triazine derivatives: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine sold under the name commerci TINOSORB S by CIBA GEIGY, Ethylhexyl triazone sold in particular under the trade name UVINUL T150 by BASF, Diethylhexyl Butamido Triazone sold under the trade name UVASORB HEB by SIGMA 3V, - Derivatives of phenyl benzotriazole: Drometrizole Trisiloxane sold under the name Silatrizole by Rhodia Chimie Methylene bis-Benzotriazolyl Tetramethylbutylphenol, sold in solid form under the trade name MIXXIM BB / 100 by FAIRMOUNT CHEMICAL or in micronized form in aqueous dispersion under the trade name TINOSORB M by CIBA SPECIALTY CHEMICALS, - Anthranilic derivatives: Menthyl anthranilate sold under the trade name commercial NEO HELIOPAN MA by HAARMANN and REIMER, - Imidazoline derivatives: Ethylhexyl Dimethoxybenzylidene Dioxoimidazoline Propionate, - Derivatives of benzalmalonate: Polyorganosiloxanes containing benzalmalonate function such as Polysilicone-15 sold under the trade name PARSOL SLX by HOFFMANN LA ROCHE - Derivatives 4,4-diarylbutadiene: -1,1-dicarboxy (2,2'-dimethylpropyl) -4,4-diphenylbutadiene - Benzoxazole derivatives: 2,4-bis- [5-1 (dimethylpropyl) benzoxazol-2 -yl- (4-phenyl) -imino] -6 (2-ethylhexyl) imino-1,3,5-triazine sold under the name Uvasorb K2A by Sigma 3V and mixtures thereof. Preferred complementary organic UV screening agents are chosen from: ethylhexyl salicylate, homosalate, ethylhexyl methoxycinnamate, butyl methoxydibenzoylmethane, octocrylene, phenylbenzimidazole sulphonic acid, disodium phenyl dibenzimidazole tetrasulfonate, benzophenone-3, benzophenone-4, benzophenone-5, 2- (4 4-Methylbenzylidene camphor, Terephthalylidene Dicamphor Sulfonic Acid, bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, Ethylhexyl triazone, Diethylhexyl Butamido Triazone, Methylene bis-Benzotriazolyl Tetramethylbutylphenol, Drometrizole Trisiloxane, Polysilicone-15, N-hexyl-diethylamino-2-hydroxybenzoyl) -benzoate 1,1-Dicarboxy (2,2'-dimethyl-propyl) -4,4-diphenylbutadiene, 2,4-bis- [5-1 (dimethylpropyl) benzoxazol-2-yl- (4-phenyl) -imino] - 6- (2-ethylhexyl) imino-1,3,5-triazine and mixtures thereof.

  The inorganic complementary photoprotective agents are chosen from pigments and even more preferably nanopigments (average size of the primary particles: generally between 5 nm and 100 nm, preferably between 10 nm and 50 nm) of metal oxides treated or untreated, for example nanopigments of titanium oxide (amorphous or crystallized in rutile and / or anatase form), iron, zinc, zirconium or cerium.

  The treated nanopigments are pigments which have undergone one or more surface treatments of a chemical, electronic, mechanochemical and / or mechanical nature with compounds as described, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, p 53-64, such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron, or aluminum salts. fatty acids, metal alkoxides (titanium or aluminum), polyethylene, silicones, proteins (collagen, elastin) alkanolamines, silicon oxides, metal oxides, sodium hexametaphosphate, alumina or glycerine.

  The nanopigments treated may more particularly be titanium oxides treated with: silica and alumina, such as the products Microtitanium Dioxide MT 500 SA and Microtitanium Dioxide MT 100 SA from TAYCA, and the products Tioveil Fin, Tioveil OP, Tioveil MOTG and TIOVEIL IPM from the company TIOXIDE, aluminum alumina and stearate such as the Microtitanium Dioxide MT 100 T product from TAYCA, aluminum alumina and laurate such as the product Microtitanium Dioxide MT 100 S from TAYCA, iron oxides and iron stearate, such as the product Microtitanium Dioxide MT 100 F from TAYCA, silica, alumina and silicone, such as Microtitanium Dioxide MT 100 products. SAS, Microtitanium Dioxide MT 600 SAS and Microtitanium Dioxide MT 500 SAS from the company TAYCA, sodium hexametaphosphate such as the product Microtitanium Dioxide MT 150 W 35 from the company TAYCA, octyltrimethoxysilane such as the product T-805 from the company Degussa, alumina and stearic acid such as the product UVT-M160 Kemira company, alumina and glycerin such as the UVT-M212 product from the company KEMIRA, alumina and silicone such as the UVT-M262 product from KEMIRA.

  Other nanopigments of titanium oxide treated with a silicone are preferably TiO 2 treated with octyl trimethyl silane and whose average elementary particle size is between 25 and 40 nm, such as that sold under the trade name "T 805 "by the company Degussa Silices, the TiO 2 treated with a polydimethylsiloxane and whose average elementary particle size is 21 nm, such as that sold under the trade name" 70250 Cardre UF TiO2S13 "by CARDRE, TiO2 anatase / rutile treated with a polydimethylhydrogensiloxane and whose average elementary particle size is 25 nm, such as that sold under the trade name "MICRO TITANIUM DIOXIDE USP GRADE HYDROPHOBIC" by the company COLOR TECHNIQUES.

  Uncoated titanium oxide nanopigments are for example sold by the company Tayca under the trade names "MICROTITANIUM DIOXIDE MT 500 B" or "MICROTITANIUM DIOXIDE MT600 B", by the company DEGUSSA under the name "P 25", by the WACKHER company under the name "transparent titanium oxide PW", by MIYOSHI KASEI under the name "UFTR", by TOMEN under the name "ITS" and by the company TIOXIDE under the name "TIOVEIL AQ".

  The uncoated zinc oxide nanopigments are, for example, those marketed under the name "Z-cote" by the company Sunsmart; those marketed under the name "Nanox" by the company Elementis; those marketed under the name "Nanogard WCD 2025" by Nanophase Technologies.

  The coated zinc oxide nanopigments are, for example, those sold under the name "Zinc Oxide CS-5" by the company Toshibi (ZnO coated with polymethylhydrogenosiloxane); those marketed under the name "Nanogard Zinc Oxide FN" by Nanophase Technologies (as a 40% dispersion in Finsolv TN, C12-C15 alcohol benzoate); those marketed under the name "DAITOPERSION ZN-30" and "DAITOPERSION Zn-50" by Daito (dispersions in cyclopolymethylsiloxane / polydimethylsiloxane oxyethylenated, containing 30% or 50% of zinc nano-oxides coated with silica and polymethylhydrogeniloxane; ); those marketed under the name "NFD Ultrafine ZnO" by the company Daikin (ZnO coated with perfluoroalkyl phosphate and a copolymer based on perfluoroalkylethyl dispersed in cyclopentasiloxane); those marketed under the name "SPD-Z1" by Shin-Etsu (ZnO coated with silicone-grafted acrylic polymer, dispersed in cyclodimethylsiloxane); those marketed under the name "Escalol Z100" by the company ISP (ZnO treated alumina and dispersed in the mixture methoxycinnamate ethylhexyl / copolymer PVP-hexadecene / methicone); those marketed under the name "Fuji ZnO-SMS-10" by the company Fuji Pigment (ZnO coated with silica and polymethylsilsesquioxane); those marketed under the name "Nanox Gel TN" by Elementis (ZnO dispersed at 55% in C12-C15 alcohols benzoate with hydroxystearic acid polycondensate).

  The nanopigments of uncoated cerium oxide is sold under the name "COLLOIDAL CERIUM OXIDE" by the company RHONE POULENC.

  Uncoated iron oxide nanopigments are for example sold by ARNAUD under the names "Nanogard WCD 2002 (FE 45B)", "Nanogard IRON FE 45 BL AQ", "Nanogard FE 45R AQ," NANOGARD WCD 2006 ( FE 45R) ", or 25 by the company MITSUBISHI under the name" TY-220 ".

  The coated iron oxide nanopigments are for example sold by ARNAUD under the names "NANOGARD WCD 2008" (FE 45B FN) "," NANOGARD WCD 2009 (FE 45B 556) "," NANOGARD FE 45 BL 345 "," NANOGARD FE 45 BL ", or 30 by BASF under the name" TRANSPARENT IRON OXIDE ".

  Mention may also be made of mixtures of metal oxides, in particular titanium dioxide and cerium dioxide, including the titanium dioxide / cerium-coated cerium-aluminum alloy mixture sold by the company IKEDA under the name "SUNVEIL". A ", as well as the mixture of titanium dioxide and zinc dioxide coated with alumina, silica and silicone such as the product" M 261 "sold by the company KEMIRA or coated with alumina, silica and glycerin such as the product "M 211" sold by KEMIRA.

  The nanopigments may be introduced into the compositions according to the invention as such or in the form of a pigment paste, that is to say in a mixture with a dispersant, as described for example in GB-A-2206339.

  The additional photoprotective agents are generally present in the compositions according to the invention in proportions ranging from 0.01% to 20% by weight relative to the total weight of the composition, and preferably ranging from 0.1% to 10% by weight relative to the total weight of the composition. relative to the total weight of the composition.

  The composition for care and / or makeup of the lips may be in the form of a lipstick stick, a liquid gloss, a paste of lipsticks, a pencil for the contour of the lips, a lip balm, a nail polish otherwise known as lip lacquer.

  The lip balm will be especially intended to protect the lips from cold and / or sun and / or wind.

  The liquid gloss, also called liquid lipstick or lip gloss, is a fluid product intended to be applied to the lips and packaged for example in a container provided with an applicator, this applicator comprising a gripping member which also serves as a closure cap of the container, and an applicator element.

  According to a particular embodiment of the invention, said natural repulping agent and / or stimulating the coloring of the lips used in the compositions of the invention is associated with at least one makeup agent with an optical effect of volume. This makeup agent with an optical volume effect is intended to reinforce the volume effect obtained by the first agent and / or to give the composition applied to the lips an immediate volumizing optical effect relayed over time by the natural volumizing effect. mediated by the first agent. The presence of the first agent in the composition also makes it possible to reduce the normally effective concentrations of the second agent to obtain the desired effect on the volume and / or color of the lips, so as to favor the natural appearance of the makeup. The invention also relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one NPY antagonist compound, and characterized in that it is in the form of a lipstick, a liquid gloss, a lip paste, a lip contour pencil, a lip balm, or a lip lacquer otherwise known as a lip lacquer.

  Advantageously, said agent will be incorporated in a system allowing its release at the skin, after application of the composition thereon. In particular, said agent can be adsorbed on or encapsulated in particle structures having a size ranging from 1 nm to a few m (10 m), such as, for example, microcapsules, microparticles, ionic-type vesicular dispersions (liposomes or oleosomes) and or nonionic (niosomes) and / or nanosphere dispersions. These particles may be advantageously porous and consist of silicates or aluminosilicates.

  Said agent will be present in the composition in an amount sufficient to obtain the desired effect, namely a volumizing or repulping effect of the lips and / or an effect on the natural coloring of the lips. For example, this amount may range from 10-8 and 10% by weight relative to the total weight of the composition, preferably from 10-6 to 5% and better still from 10-4 to 2%, and more preferably 10 to 10% by weight. -2 to 1% by weight relative to the total weight of the composition.

  The composition may be in any galenic form suitable for topical application to the lips, in particular one of those described previously in the description.

  In a particular composition of the invention, said agent is associated with at least one makeup agent having an optical effect on the volume of the lips, preferably chosen from goniochromatic pigments, reflective particles and their mixtures, as described above.

  Examples of such compounds are described above.

  The composition may also comprise at least one agent chosen from fillers, dyestuffs, cosmetic active agents, thickeners, surfactants, moisturizers, softeners, sequestering agents, perfumes, neutralizers, preservatives, antioxidants, UV filters, bactericides, trace elements and mixtures thereof.

  Examples of such compounds are described previously in the description.

  The invention also relates to a lip care process, characterized in that a composition as defined above is applied to the lips. The examples given below are presented for illustrative and non-limiting purposes of the invention.

  EXAMPLES Example 1 Demonstrating the Presence of Neuropeptide Y in the Lips - Immunolabeling The detection was carried out by fluorescent immunostaining on tissue sections (eyelids and lips).

The tissues collected are fixed in Zamboni medium at 4 ° C. and then frozen at -80 ° C. The sections are then made at 10 μιη and are incubated with the primary antibody (anti-NPY, Chemicon AB1915, 1/300, 3h). ). After rinsing, they are incubated with fluorescent secondary antibody (coupled with Alexa 488, Molecular Probes, 1 h). Finally, they are rinsed then counter-stained with DAPI and mounted on slides. Image Capture Image captures were performed on a fluorescent Pathfinder Morphoscan system. Figures 1 and 2: the clichés obtained demonstrate the presence of NPY in the lips, unlike the eyelids. The immunofluorescence of the stratum corneum which appears on the eyelid images is only an artifact of autofluorescence. In conclusion, irrespective of the level of tissue innervation, the lips have the particularity of expressing the NPY very strongly. Example 2 - Lip balm compositions - BIBP3226: (n (R) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] argininamide) 0.25% - Carnauba wax 12.75% - Oxypropylenated lanolin wax (5 propylene oxides) 15.00% - Castor oil qs 100% 5 After melting of Carnauba and lanolin waxes at 100 ° C., the castor oil containing the acexamic acid is introduced after cooling. (temperature less than or equal to 40 C), the mixture is mixed together and poured into a suitable mold.

Claims (16)

  1. Cosmetic use of at least one neuropeptide Y (NPY) antagonist compound for preventing and / or treating disorders of weakened or damaged lips.   2. Use according to claim 1 for preventing and / or treating dry lips and / or redness and / or desquamations and / or cracks lips.   3. Use according to claim 1 or 2 to reduce the redness of the lips and give them a uniform color.   4. Cosmetic use of at least one neuropeptide Y (NPY) antagonist compound for preventing and / or treating sensitive lips.   5. Use according to claim 4 for preventing and / or treating irritable or intolerant lips. 20   6. Use according to claim 4 or 5 for preventing and / or treating dysaesthesic sensations and / or sensations more or less painful and / or tugging and / or tingling and / or tingling and / or heating and / or itching and / or discomfort . 25   7. Use of at least one neuropeptide Y (NPY) antagonist compound for the preparation of a composition intended for the treatment of painful and / or irritated and / or cracked lips and / or having one or more signs of inflammation. 30   8. Use according to any one of claims 1 to 7, characterized in that said compound is chosen from: 1. Compounds of formula (1) 10R Ar 1 -SO 2 NCH-CH 2 C 3 HC = QC HR'xx, R in which - Ar1 represents naphthyl, phenyl, quinolyl or isoquinolyl optionally substituted with Cl, F, (C1-C4) alkyl, (C1-C4) alkoxy, hydroxyl or (C1-C4) dialkylamino; Ar 2 represents phenyl or thienyl, optionally substituted by Cl, F, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy or hydroxyl; - R1, R2 and R'2 represent independently of each other hydrogen, (C1-C4) alkyl or R1 represents nothing and N is bonded to Ar2 and optionally R2 and R'2 form a double bond, or R1 or R2 is bonded to Ar2 and represents (C1-C3) alkylene; R3 and R4, which are identical or different, represent hydrogen, (C1-C4) alkyl or form, with the nitrogen atom to which they are bonded, a (C5-C7) saturated heterocycle chosen from pyrrolidine, piperidine and hexahydroazepine; - Z1 represents (C1-C12) alkylene interrupted or optionally substituted with (C5-C7) cycloalkyl or phenyl; Q 1 represents methyl, amino, (C 1 -C 4) alkoxycarbonylamino, (C 1 -C 4) alkylamino, di (C 1 -C 4) alkylamino, pyrrolidinyl, piperidino, morpholino, piperazinyl, (C 1 -C 4) alkyl-4-piperazinyl, amidino, (C1-C4) alkylamidino, guanidino, (C1-C4) alkylguanidino, pyridyl, imidazolyl, pyrimidinyl, indolyl, hydroxy, (C1-C4) alkoxy, (C2-C8) alkoxycarbonyl, N- [amino-C1-C4] alkyl ] -N - [(C1-C4) alkyl] amino, carbamoyl or phenyl optionally substituted with Cl, F, (C1-C4) alkyl, (C1-C4) alkoxy or hydroxyl; Q2 represents hydrogen or (C1-C4) alkyl; - Q3 represents hydrogen or (C1-C4) alkyl or Q1 and Q3 are linked to form a heterocycle and together represent (C2-C3) alkylene while Z1 represents nothing, in the form of pure enantiomers or their mixtures in any proportions, as well as their addition salts with acids; II-Analogues of Raloxifene, III-Phenylsulfonylquinolines of Formula (IV) R'y in which Ry is an optionally substituted aryl, -R'y is -NO2, -CN, -CO2R3y in which R3y is H, alkyl or aryl Wherein R3y is as defined above, or R3yO where R3y is as defined above, or R3y in which R3y is as defined above, R2y is -NH2, -OH or ùSH, and its salts; IV - Bénextramine and its analogues V - Derivatives of inositol phosphate VI The compounds of formula (V) in which: - Ar 'is phenyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl Or 4- or 5-pyrimidyl, each optionally mono or di-substituted with halogen, hydroxy, or linear or branched lower alkyl chain having 1 to 6 carbon atoms; A ', W', X ', Y' and r are the same or different and represent hydrogen, halogen, hydroxy, linear or branched lower alkoxy chain having 1 to 6 carbon atoms; - R'1 and R'2 are identical or different and represent a hydrogen, a linear or branched lower alkyl chain having 1 to 6 carbon atoms; R'3 and R'4 are the same or different and represent hydrogen, a linear or branched lower alkyl chain having 1 to 6 carbon atoms; and R'9 represents hydrogen, a straight or branched lower alkyl chain having 1 to 6 carbon atoms, or phenyl; and their salts, VII - Compounds of formula (VI) Ta-Za-NR 'a- (R2aCR3a) -CO-Ya- (CH2) na-Ra in which - na represents 0, 1, 2, 3, 4, or 5; Ra represents a hydrogen atom, a phenyl or naphthyl group optionally mono- or disubstituted with an identical or different substituent chosen from a fluorine, chlorine, bromine or an iodine atom, a cyano or alkyl group, phenyl, hydroxy, alkoxy, dialkylaminoalkoxy, hydroxyphenyl, phenylalkoxy, alkylcarbonyl, amino, alkylamino, dialkylamino, alkylsulfonylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonyloxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonyloxy, alkylsulfonyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl trifluoromethyl, trifluoromethoxy, trifluoro methylthio, aminoalkyl, alkylaminoalkyl, aminocarbonylaminoalkyl, benzoylamino, alkanoylaminoalkyl, alkoxycarbonylaminoalkyl, benzyloxycarbonylaminoalkyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, aminosulfonylamino, alkylaminosulfonylamino, dialkylaminosulphonylamin, cyanamino, amine nocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, aminosulfonylaminoalkyle, alkylaminosulfonylaminoalkyle, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, aminosulfonylalkyl, alkylaminosulfonylalkyl, alkylsulfonyl, aminosulfonyloxy, alkylaminosulfonyloxy, dialkylaminosulfonyloxy or a group cyanoguanidino, an aminophenyl group or aminonaphtyle disubstituted by chlorine or bromine atom, the substituents which may be the same or different, or a hydroxyphenyl or hydroxynaphthyl group disubstituted by a chlorine or bromine atom or by alkyl or alkoxy groups, the substituents may be the same or different, or a diphenylmethyl group, a substituted aminocarbonylalkyl group on the alkyl part with a hydroxyphenylalkyl group or a (2,2-diphenylethyl) aminocarbonylaminophenyl group, a 5-membered heteroaryl group connected by a carbon or nitrogen atom, said heteroaryl aryl comprising an imino group optionally substituted by a (C 1 -C 6) alkyl group or a phenyl group and an oxygen, sulfur or nitrogen atom, or a 6-membered heteroaryl group connected by a carbon atom, said heteroaryl comprising one or two nitrogen atoms, as well as the 5- or 6-membered heteroaromatic rings defined above which constitute a heteroaromatic bicycle with two carbon atoms neighboring the heteroaromatic ring and a 1,4-butadienylene group and further, all the mono- or bicyclic heteroaryl groups mentioned above may be monosubstituted on the carbon skeleton by a fluorine, chlorine or bromine atom, by an alkyl, alkoxy, hydroxy, phenyl, nitro, cyano, carbonyl or alkoxycarbonyl group, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fluoro methyl, difluoromethyl, trifluoromethyl, alkanoyl, aminosulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl, or disubstituted by a fluorine, bromine or chlorine atom, with methyl, methoxy or hydroxy groups, the substituents possibly being identical or different, a phenyl group substituted with a (1,5-dihydro-2,4 (3H) -dioxo imidazol-3-yl) alkyl or with a [1,2-dihydro-3,5 (4H) -dioxo-3H-1,2,4-triazol-4-yl] alkyl residue, wherein the imidazole or triazole moiety is substituted with 1 or 2 phenyl groups, a cycloalkyl group having from 4 to 8 carbon atoms optionally substituted by a hydroxy, amino, alkylamino or dialkylamino group, the substituents described above not being linked to the position 1 of the remainder cycloalkyl, when Y represents an oxygen atom, a group 1 - [[[5,11-dihydro-6 (6H) -oxo-pyrido [2,3-b] [1,4] benzodiazepin-11-yl] carbonyl] methyl] -4-pipéhdinyl or a 3-hydroxy-1-propin-1-yl group, a 2,3-dihydro-1H-isoindol-2-yl group optionally substituted on the nitrogen atom by a diphenylaminocarbonyl group, or a hydroxy group, when Y is an oxygen atom or a group R 1 is a hydrogen atom, a linear or branched (C 1 -C 10) alkyl group, a cycloalkyl group having 3 to 7 carbon atoms, a phenyl group, if any, substituted by a hydroxy or hydroxyalkyl group, or a phenylmethyl group optionally substituted on the phenyl part by a hydroxy or hydroxyalkyl group, - R2a is a (C1-05) unbranched alkyl substituted in the omega position by an amino or alkylamino group protected by a protecting group of the amino group, with a dialkylmino, N-alkylbenzylamino, aminocarbonyl, aminocarbonylamino, aminoethylimine, aminoiminomethyl, amino (hydroxyimino) methyl, amino (alkoxyimino) methyl, amino (nitroimino) methyl, [amino (nitroimino) methyl] amino group, amino (cyanimino) methyl, [amino (cyanimino) methyl] amino, [(alkylamino) iminomethyl] amino, [(alkylamino) (alkylimino) methyl] amino, [amino (alkylimino) methyl] amino, 2-aminoimidazol-1-yl , (5-amino-4H 1,2,4-triazol-3-yl) amino, (5-amino-4H-1,2,4-triazol-3-yl) methylamino, (3-amino-1,2,4-oxadiazole) -yl) amino or (5-amino-1,2,4-oxadiazol-3-yl) amino or by imidazol-4-yl, imidazol-2-yl, 1-methyl-imidazol-2-yl, imidazol 2-yl-amino, imidazol-2-yl-methylamino, (4,5-dihydro-1H-imidazol-2-yl) amino optionally substituted on the carbon by one or two methyl groups, or a phenyl or phenylmethyl group optionally substituted on the aromatic rings by a cyano, iminomethylamino, cyaniminomethylamino, (methylamino) methyl idenamino, aminoiminomethyl, amino- (hydroxyimino) methyl, amino (alkoxyimino) methyl, hydrazinoiminomethyl, amino (cyanimino) methyl or guanidino group or with an imidazol group -2-yl, 1-methyl-imidazol-2-yl, 4,5-dihydro-1H-imidazol-2-yl optionally substituted on the carbon atoms by one or two methyl groups, in which in the aminoiminomethyl groups, Amino (hydroxyimino) methyl and guanidino mentioned s in the definition of R2a above, one or more hydrogen atoms connected to the nitrogen atom, independent of each other, may be replaced by alkyl groups or in which two hydrogen atoms connected to different Nitrogen atoms may be replaced by an alkyl bridge having 2 to 4 carbon atoms and for which the hydrogen atom of a group HN <, HN = or H 2 N in the radical R2a may be substituted by an alkoxycarbonyl group having of 2 to 7 carbon atoms, with a phenylalkoxycarbonyl group in which the alkyl is (C1-C6), phenyloxycarbonyl, R15a-CO-O- (R16aCR17a) -O-CO or a group ( R18aO) PO (OR19a) wherein: R15a is a (C1-C15) alkyl group, a (C3-C7) cycloalkyl group, a phenyl group or a phenylalkyl group in which the alkyl is (C1-C3), R16a and R17a, which may be identical or different, represent a hydrogen atom, a (C1-C6) alkyl group, or one of the residues R16a and R17a represents C3-C7 cycloalkyl group or phenyl group, R18a and R19a, which may be identical or different, represent a hydrogen atom, (C1-C4) alkyl groups, benzyl or phenyl groups, - Ria is an atom of hydrogen, a (C 1 -C 7) alkyl group or a (C 4 -C 7) cycloalkyl group, - Ta is a hydrogen atom, a phenyl group or a 5-membered heteroaryl group connected by a carbon atom or a carbon atom. nitrogen and comprising a nitrogen, oxygen or sulfur atom optionally substituted by an alkyl group, or comprising a nitrogen atom optionally substituted with an alkyl group and a sulfur, oxygen or nitrogen atom; additional nitrogen, or when Za is a bond, Ta is a protecting group of an amino group or the residues (T1aT2aUa) - (CH2) m- or T3,0-, wherein Ti, at T3a, the same or different are phenyl groups or 6-membered heteroaryl groups linked by carbon atoms, which depending on the case com take one or two nitrogen atoms, 5-membered heteroaryl groups connected by carbon or nitrogen atoms, comprising a nitrogen atom optionally substituted by an alkyl, sulfur or oxygen group, or comprising an atom nitrogen optionally substituted by an alkyl group and a nitrogen, sulfur or additional oxygen atom, in which a 1,4-butadienylene bridge may be formed between two carbon atoms neighboring the 5-membered heteroaryl groups; 6 links mentioned above in the definition of Ta remains; the bicyclic aromatic or heteroaromatic rings thus formed may also be bonded to a carbon atom of the 1,4-butadienylene group and, moreover, both the phenyl groups, the 5 or 6-membered heteroaryl groups and the bicyclic aromatic or heteroaromatic rings may be mono or disubstituted on the carbon skeleton by fluorine, chlorine, bromine or iodine atoms or by cyano, hydroxy, amino, dimethylamino, diethylamino, N-ethylmethylamino, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, acetylamino, propionylamino groups, methanesulfonylamino, methansulfonyloxy, phenyl, phenylmethoxy, 2-phenylethoxy, alkyl, or alkoxy or trisubstituted with a group amino or hydroxy and two atoms of chlorine or bromine or with a hydroxy group and two alkyl or alkoxy groups, the substituents being identical or different, and the alkyl and alkoxy parts mentioned above comprising from 1 to 4 atoms carbon atoms, hydrogen atoms, (C1-C12) alkyl groups, cycloalkyl groups having 3 to 10 carbon atoms, bicycloalkyl or tricycloalkyl groups having 6 to 12 carbon atoms or T1a and T2a together represent a linear chain C 1 -C 7 alkylene group, Ua is the> CH group, in which the hydrogen atom may be replaced by an alkyl, phenyl, hydroxy, alkoxy, alkanoyloxy, alkoxycarbonyl alkanoylamino group, wherein alkyl or the alkoxys mentioned above may comprise, according to the case of 1 to 3 carbon atoms, and the alkanoyls mentioned above may comprise 2 or 3 carbon atoms, or the> CHCH 2 group or the nitrogen atom, m represents 0, 1, 2, or 3 or Ta is a group (T1aT2aUa) - (CH2) ma in which T'a, T2a, Ua and ma are as defined above with the difference that aromatic rings or mono- or bicyclic heteroaromatics mentioned above for T1a and T2a are linked in either by a bond, a -CH2-, -C (CH3) 2-, -CH2CH2-, -CH = CH- or -NHCO- bridge, - Ya is an oxygen atom or a group -NR4a, in wherein R4a is as defined above with R1a, the radicals of R1a and R4a may be the same or different, and - Za is a single bond defined by -CO-, -CH2-, -SO-, or - SO2-, and, unless otherwise stated, the alkyl and alkoxy moieties mentioned above may comprise from 1 to 3 carbon atoms, and tautomers, diastereomers, enantiomers, mixtures and salts; The compounds of the formula wherein R "is defined by the formula: R" 1 R "2 N - (CH 2) - in which R" 1 represents a non-phenyl group substituted or substituted by one or two halogen atoms, a (C1-C3) alkyl group or a pyridinyl ring unsubstituted or substituted by one or two halogen atoms, a (C1-C3) alkyl group or a (C1-C3) alkoxy group R 2 represents a hydrogen atom, a (C 1 -C 3) alkyl group, a phenyl group optionally substituted by one or two halogen atoms or by a (C 1 -C 3) alkyl group or by a Cl group -C3) alkoxy, a benzyl or heteroaryl group unsubstituted or substituted by one or two halogen atoms or a (C1-C3) alkyl or (C1-C3) alkoxy group, n "represents 1, 2, 3 or 4 or wherein R "is defined by the formula: R" wherein R "3 represents a pyridinyl ring unsubstituted or substituted by one or two halogen atoms, a (C1-C3) alkyl or (C1-C3) group ) alkoxy, R "4 represents is a hydrogen atom or a phenyl group optionally substituted by one or two halogen atoms or by a (C 1 -C 3) alkyl group or by a (C 1 -C 3) alkoxy group, R "5 represents a hydrogen atom or a methyl or hydroxy group and Z "represents a single bond, an oxygen atom, or a sulfur atom and p" represents 1, 2 or 3 m "represents 1,2 or 3 and R" O represents an atom of hydrogen or a methyl group, as well as their pharmaceutically acceptable salts; IX - Dihydropyridines of the formula 58 ## STR2 ## wherein R 1 is lower alkyl; R 3 '8 R 3 are independently selected from cyano and lower alkyl; R 4 is selected from CO 2 R 1, cyano and N - R5x is selected from hydrogen, halogen, hydroxyl, lower alkyl, lower alkenyloxy and lower alkoxy; B'8St -NH- or a covalent bond; nx represents an integer of 2 to 5; and 3x is selected from the group consisting of: and solid or dotted lines representing a single or double bond, as well as their addition salts or solvates X - Compounds of formula Tyr-Pro-Ser-Lys-Pro ## STR5 ## Arg-Tyr-Tc (IX) in which -Xxx2 and Xxx3 are Ser or Ala, -Xxx4 and Xxx5 are Leu, Ile, Met, Nle (Norleucine) or Val-Tc is OH, O (C1-C4) alkyl, NH2 or NH (C1-C4) alkyl, -s is an integer from 1 to 11, and their XI - The compounds of formula Zb-Ak1-Bk2-BPk3-Dk4-Ek5-Fk6-Gk7-DP-Thr-Bp'-Glu-BP "-K-NH in which k1, k2, k3, k4, k5 , k6 and k7 represent zero or 1, their sum being at least 1, A is Phe or Tyr; B is Pro, Ser, Ala, Gly, Abu, Cys, Pro-Ser, Cys-Ser, Ala-Ser, Gly-Ser, Abu-Ser or Pro-Ala, Abu being 2-aminobutyric acid; BP, BP 'and BP' are amino acids with a basic side chain, D is Pro or Cys, E is NH- (CH2) t-CO, t is 0-10, F is Cys, Abu Gly or Ala; is Ile-Asn, Leu-Asn, Val-Asn or Asn, DP is the residue of a dipeptide formed by lipophilic amino acids, K is Phe or Tyr, Zb is hydrogen, an amino protecting group or a group benzyl, (C2-C10) acyl or (C1-C5) alkyl and in which two Cys residues may be linked by a disulfide bridge, as well as their salts; XII - cyclic or linear compounds, of formula (XI) (Xxxa- Xxxb-Xxxc-Xxxd-Xxxe-Xxxf-Xxxg-Xxxh-Xxxx-Xxxj) n where Xxxa, Xxxb, Xxxb, and Xxxi may not exist, or Xxxa is P1 or Cys; Xxxb is Cys, P1, or one or two amino acids; Xxxc is P1, Cys, Ser, Thr, Ala, or Gly; Xxxg is R1, Cys, Ser, Thr, Ala or Gly; Xxxe is Leu, Ile, Val or Nle; Xxxg is Arg, Lys or His; Hxxg is Arg, Lys, His, Val, Leu, Ile or Nle; Xxxh is Tyr, Phe, Trp, His, Lys or Arg; Xxx; NH 2 group or an ester group or one or two amino acids; xxx; is Cys or P2; P1 is hydrogen or a P-CO group where P is hydrogen, a glycosyl, nucleosyl or lipolyl radical or a (C1-C20) alkyl group, optionally containing double bonds and substituents chosen from halogens and the group NO 2, NH 2, OH, sulfo, phospho, carboxy and alkyl; P2 is NP12P13 or OP14 wherein P12 and P13 are hydrogen or alkyl, cycloalkyl, N-glycosyl, N-lipolyl, aralkyl or aryl, optionally substituted with halogen or with NO2, NH2, OH, sulfo, phospho, carboxy or alkyl; and P14 represents hydrogen or an alkyl, cycloalkyl, aralkyl, -O-glycosyl, -O-lipolyl, aralkyl or aryl group, optionally substituted by a halogen or a NO2, NH2, OH, sulfo, phospho, carboxy or alkyl, with the limitation that - when Xxxb does not exist or represents Cys or P1, then Xxxa is non-existent, - when Xxxd is Cys or P1, then Xxxc is non-existent, - when Xxx; is NH2 or an ester, then Xxx; is nonexistent; Xlll - Compounds of formula H-Tyr-Pro-S + r-Lys-Fers-Asp-Asn-Pro-tolu-(I) Asp-Ala-Pro-Afa-Glu-Asg-cx6-Ali-; rg-Tyr-Tyr-Ser-A [α-Leu-Arg-Tyrr1le-Asn-Leu-11e-Thr-Arg-Xxx7-8-L1 w (CH2) 2-P3 wherein z is 0,1 or 2 Xxx6 is Met or Leu; Xxx7 is Glu, (R) -Glu, Pro or (R) -Pro; Xxx8 is Arg, (R) -Arg or (R, S) -Arg; L1 is O or NP ', P' being H or alkyl; and P3 is phenyl or naphthyl unsubstituted or substituted with one or two F, Cl, Br, alkyl, phenyl, OH, (phenyl) alkoxy, alkylcarbonyl, NH2 (optionally substituted by one or two alkyls), alkylsufonyl, alkyl- or an alkoxycarbonylamino, COOH, alkoxycarbonyl, NH2CO (optionally substituted with one or two alkyls), alkylcarbonyloxy, alkylsulfonyloxy, CH2OH, 1- or 2-hydroxyethyl, (alkyl) aminosulfonyl, cyanamino, aminocarbonylamino (optionally substituted with one or two alkyls) or NH2C (= N.CN) NH; a 5-membered aromatic heterocycle containing oxygen, sulfur or nitrogen, an imino group or an imino group containing oxygen, sulfur or nitrogen; a 6-membered aromatic heterocycle with one or two nitrogen atoms; said heterocycles may be C-substituted by (C 1 -C 6) alkyl or phenylalkyl and optionally fused to benzene and optionally also substituted by F, Cl, Br, (C 1 -C 6) alkyl, alkoxy, OH, phenyl, NO 2, NH 2 (optionally substituted by one or two alkyls or an alkanoyl), CN, COOH, alkoxycarbonyl, NH 2 CO (optionally substituted by one or two alkyls), CH 2 F, CHF 2, CF 3, alkanoyl or NH 2 SO 2 (optionally substituted with one or two alkyls) or with two F, Cl, Br, methyl, methoxy or OH; a phenyl group substituted with a [1,5-dihydro-2,4- (3H) -dioxoimidazol-3-yl] alkyl group or a [3,5-dihydro-4H-dioxo-3H-1 group, 2,4- 62 triazol-4-ylalkyl wherein the imidazole and triazole groups may be substituted with one or two phenyls; alkyl and alkoxy groups containing from 1 to 3 carbon atoms, and their salts; XIV - Compounds (XIII) CH3CO-D-Cys-Leu-Ife-Thr-Arg-Cys-Arg-Tyr-NH2 and (XIV) I-Cys-Pro-Cys-Tyr-Arg-Leu-Arg-Tyr -NH2 Ile-Cys-Pro-Cys-Tyr-Arg-Leu-Arg Tyr-N H2 XV - The extracts with NPY-antagonist activity obtained by extracting a spongier, Orina sp. Gray (or Gellius sp.); XVI - Extracts of fermentations of strains of Aspergillus, XVII - The products, in particular the extracts obtained by fermentation of strains of Actinomycetaceae.   9. Use according to any one of claims 1 to 8, characterized in that said agent is present in the composition in an amount ranging from   10-8 to 10% by weight relative to the total weight of the composition, preferably from 10-6 to 5%, and even more preferably from 104 to 2% by weight relative to the total weight of the composition. 10. Use according to any one of claims 1 to 9, characterized in that the NPY antagonist has a specific affinity for the NPY Y1 receptor.   11. Use according to any one of claims 1 to 10, characterized in that said agent is adsorbed or incorporated into particles of size ranging from 1 nm to 10 pm.   12. A composition comprising, in a physiologically acceptable medium, at least one NPY-antagonist compound and characterized in that it is under the (XIII) (X1V) form of a lipstick, a liquid gloss, d a lipstick, a lip contour pencil, a lip balm, or a lip polish.   13. Composition according to claim 12, characterized in that the composition comprises in others cosmetic active agents are chosen from agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation, moisturizing agents, anti-pollution agents or anti-radical, soothing agents, healing agents, UV filters.   14. Composition according to one of claims 12 or 13, characterized in that said compound is present in the composition in an amount ranging from 10-8 to 10% by weight relative to the total weight of the composition, preferably from 10 to 10% by weight relative to the total weight of the composition, preferably from 10 to 8% by weight relative to the total weight of the composition. -6 to 5%, and even more preferably 10-4 to 2% by weight relative to the total weight of the composition.   15. Composition according to any one of claims 12 to 14, characterized in that said agent is adsorbed or incorporated into particles of size ranging from 1 nm to 10pm.   16. Cosmetic process for beautifying damaged lips and / or treating weakened lips or sensitive lips, characterized in that a composition as defined in Claims 12 to 15 is applied to the lips.